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Abstract 
Protein aggregation is deleterious to human health and detrimental to therapeutic 
shelf-life. The physical processes that induce aggregation are the same processes that 
drive productive folding reactions. As such, protein aggregation is a non-productive form 
of protein folding. To gain insight into the steps that serve as a partition between the 
folding and aggregation reactions, the folding mechanisms of several β-rich proteins with 
links to human disease or medicine were examined.  
In the ALS-linked protein, SOD1, a subpopulation of the unfolded ensemble is 
found to be a common source of both nonnative structure and frustrated folding. These 
behaviors are only observed upon the reduction of the intrinsic disulfide bond, indicating 
that this covalent interaction wards against aggregation. The nonnative structure presents 
an attractive target for the development of new therapeutic agents. 
In VH domains from therapeutic mAbs, the intramolecular disulfide bond protects 
against aggregation. However, it can also introduce complexity to the folding mechanism. 
This complexity is linked to the formation of a strained orientation of the disulfide bond. 
This strained orientation of the disulfide in certain VH domains is energetically 
unfavorable enough to disrupt the formation of the disulfide in the full length mAbs. The 
novel relationship observed between disulfide orientation, folding complexity, and 
incomplete oxidation warrants further examination in other Ig domains.  
Overall, these results demonstrate that mapping the folding free energy landscape 
for proteins with roles in human disease or therapeutics can provide valuable insights for 
developing and improving treatment options.   
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responsible for the experimental design. I performed the experimental work. I performed 
the data analysis with input and guidance from Dr. Bilsel. All authors interpreted the 
results collaboratively. I wrote the manuscript with input from all parties.  
The work presented in Chapter III is currently under review at Biophysical 
Journal as Cohen NR, Kayatekin C, Zitzewitz JA, Bilsel O, and Matthews CR. Friction-
limited folding of disulfide-reduced SOD1: Implications for ALS-linked aggregation. Dr. 
Matthews, Dr. Kayatekin, Dr. Ztizewitz and I were responsible for the experimental 
design. Dr. Kayatekin and I performed the experimental work. Dr. Bilsel and I designed 
the novel analysis method. I performed the data analysis. All authors interpreted the 
results collaboratively. I wrote the manuscript with input from all parties.  
The work presented in Chapter IV is a preliminary report of the results of a study 
that explores the folding mechanism of several immunoglobulin variable heavy domains 
from therapeutic antibodies. The chapter is adapted from a manuscript draft in prep 
targeted to Protein Science. The original project was started as a collaboration between 
our group and Dr. Yung-Hsiang Kao’s group at Genentech. Dr Xiren Yu provided me 
with small amounts of the purified domains for initial experiments. After the initial 
period she provided cell pellets from which I could purify more as well as the 
methodology to do so, which I scaled up as necessary. Dr. Xiren Yu crystallized the 
 xiii 
domains under the direction of Dr. Kao. The experimental design was performed by Dr. 
Matthews, Dr. Kao and myself. I performed all the experimental work and the data 
analysis. Dr. Matthews and I interpreted the results and formed conclusions with input 
from Dr. Kao. I wrote the manuscript draft with input from Dr. Matthews. 
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Chapter I – Introduction 
BACKGROUND 
Proteins are structurally and functionally diverse macromolecules that mediate 
many of the biological processes responsible for life. Ranging from enzymes that 
catalyze metabolic reactions to cytoskeletal components that give cells structure and 
support while also providing intracellular transport mechanisms to signal receptors that 
offer a means of intercellular communication and a system for adaptive response to 
external stimuli, proteins play crucial roles throughout biology . In order to specifically 
and efficiently perform such wide-ranging functions, proteins must be able to adopt 
unique structures, which they do through a process termed “folding”.  
Despite the wide array of folded structures all proteins begin in a similar form, as 
unfolded and expanded polypeptide chains of varying lengths. From this initial state, each 
protein is able to fold into a unique, stable and functional native state. How can various 
sequences of the same 20 amino acids encode such a multitude of three-dimensional 
protein structures? How does the primary sequence influence the mechanism by which a 
protein reaches its native state? These are the central questions that the protein folding 
field seeks to answer. 
 
The landscape view of the protein folding  
In seminal work that was later awarded the Nobel prize, Christian Anfinsen 
discovered that Ribonuclease was able to spontaneously regain its enzymatically active 
form when removed from a denaturing environment1. This work demonstrated that a 
polypeptide chain contains the information required to reach its native form, suggesting 
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that a protein’s native state is the conformation with the lowest free energy and thus the 
most thermodynamically favored state. Concurrently, Cyrus Levinthal noted that due to 
the length of polypeptide chains and the number of potential phi and psi bond angle 
arrangements, a protein would have an inordinately large number of possible 
conformations2. Consequently, sampling each one until finding the one native state, even 
if done rapidly, would take timescales far beyond the limits imposed by biology. This 
thought experiment implies that protein folding is a sequential process through a defined 
pathway, rather than a random search process.  
By combining these two basic principles the energy landscape model of protein 
folding was developed3–5. In this model the energy landscape is represented with a 
funnel-shaped diagram in which the width corresponds to the conformational entropy and 
the height denotes the free energy of the molecule. At the top of the funnel is the 
ensemble of unfolded states of the polypeptide; these unfolded states lack order or 
structure and thus have large conformational entropies and high free energies. The 
bottom of the funnel denotes the folded, native state of the protein; this well-defined 
structure represents the free energy minima of the system and is conformationally 
constrained. The sides of the landscape represent the pathway a polypeptide chain may 
take on its route to the native state and they can be either smooth, i.e., two-state folding in 
which unfolded chains fold directly to the native state, or rugged, when unfolded chains 
form partially-folded intermediates prior to the native state5. Mapping the energy 
landscape of proteins can provide insights into how different regions of sequence drive 
the distinct steps of folding. An example of a folding landscape is shown in Figure 1.1.  
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Figure 1.1: Folding free energy landscape 
A representative folding free energy landscape is shown. During folding polypeptide 
chains move from the highest energy expanded unfolded state (top) towards the lowest 
energy native state (bottom). During this process partially-folded states (upper right) or 
stable intermediates (lower right) can form prior to reaching the native state.  
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PROTEIN AGGREGATION 
While the properly folded form of a protein is the biologically active and relevant 
structure, it is not the only potential outcome of folding reactions. Proteins can also 
aggregate. Aggregation is the term used to describe the mechanism through which 
multiple polypeptide chains form intermolecular associations resulting in higher order 
nonnative structures. There is an array of nonnative structures that may be formed during 
the process of aggregation that range from small soluble oligomers6 to macroscope 
aggregates that can form either highly ordered structures, such as amyloid fibrils7, or 
remain amorphous and lack well-defined structural components8. 
 
Aggregation is detrimental to human health and to therapeutics 
Aggregation has significant impacts on human disease and therapy. Large 
insoluble protein aggregates are a hallmark of multiple forms of devastating human 
diseases such as neurodegeneration and amyloidosis9. The neurodegenerative diseases 
Alzheimer’s, amyotrophic lateral sclerosis, Parkinson’s, as well as prion diseases have all 
been linked to misfolding and subsequent aggregation of proteins, and recent evidence 
suggests similar processes may play a role in other maladies. For example, amyloidosis is 
a group of diseases that affect a range of tissues in the body all of which have the 
hallmark of forming large amyloid fibril aggregates that interfere with normal biological 
functions10. Protein aggregation disorders can even be instigated by other ailments, such 
as the light chain amyloidosis that often accompanies multiple myeloma11. Table 1.1 lists 
some aggregation-linked diseases and the related proteins. 
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Table 1.1: Diseases linked to protein 
aggregation and the relevant proteins 
Disease Protein 
Alzheimer’s Disease Amyloid β12 
Parkinson’s Disease α-synuclein13 
Tauopathies τ-proteins14 
Frontotemporal Lobar Degeneration TDP-43 and FUS-TLS15 
Amyotrophic Lateral Sclerosis SOD1, C9ORF7216 
Huntington’s Huntingtin17 
Prion Diseases Prion Protein18 
  
Type II Diabetes Islet Amyloid Polypeptide19 
  
Transthyretin amyloidosis Transthyretin20 
Light Chain amyloidosis Immunoglobulin Light Chains21 
Heavy Chain Disease Immunoglobulin Heavy Chains22 
AA amyloidosis Amyloid A protein23 
Dialysis-related amyloidosis β2 microglobulin24 
  
Cataracts Crystallin25 
Retinitis Pigmentosa Rhodopsin26 
  
Medullary thyroid carcinoma Calcitonin27 
Multiple Myeloma Immunoglobulin Light Chains11 
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Aggregation also interferes with human health by negatively impacting 
therapeutic molecules used in treating human disease. Aggregated therapeutics can lead 
to an adaptive immune response in patients resulting in the production of anti-drug 
antibodies that lead to therapeutic immunity or, rarely, development of an auto-immune 
disease28–30. Beyond that, aggregation can occur prior to delivery of the therapeutic, such 
as during the production process or storage, leading to a loss of activity over time 
indicating that the therapeutic has a poor shelf life31–33. Short shelf lives result in 
increased production costs and these, in turn, increase medical costs for patients.  
 
Why do proteins aggregate? 
The formation of protein aggregates seems to contradict the landscape model, as 
two inherent assumptions of the model are that folding to native state is the most 
kinetically accessible and most thermodynamically favorable state available to a 
polypeptide chain. If these assumptions were true, then how could a protein aggregate? 
Examination of the steps in aggregation, the structures formed, and how these are related 
to productive folding, begins to reveal an answer. 
Some aggregates, especially those that form fibrillar structures, have been shown 
to be remarkably stable and difficult to resolubilize34,35. High resolution structural data 
has demonstrated that amyloid fibrils are composed of cross-β sheets stabilized by strong 
hydrogen bonding networks inside of hydrophobic cores36,37 and that introduction of 
electrostatic residues38 or proline residues39 disrupt these cores and destabilizes the 
fibrils. These behaviors are remarkably similar to that of native states, which are 
themselves stabilized by dense packing of hydrophobic cores40 and favorable surface 
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electrostatic interactions41. The shared behavior of native states and end stage aggregates 
indicates that the same physiochemical forces that drive productive folding also drive 
aggregation. This observation along with the unusual stability of aggregates suggests that 
not only are they thermodynamically stable, but that they are even more 
thermodynamically favorable than the native state.  
The earliest step in some aggregation reactions has been shown to be the 
formation of partially-folded or misfolded states42–47. These aggregation-inducing states 
are formed during search for the native conformation and may even contain residual 
aspects of the native structure, suggesting that these steps are also a part of the productive 
folding mechanism. After these early steps, aggregation is generally irreversible, meaning 
end stage aggregates cannot be returned to the native conformation48.  
The observations that aggregation can (1) be thermodynamically favorable, (2) is 
driven by the same forces as productive folding and (3) may involve some of the steps 
early in the productive folding reaction leads to the concept that the two processes are 
inexorably linked. What this means is that protein aggregation is another portion of the 
free energy landscape a diagram of which is shown in Figure 1.2. Consequently, mapping 
the nexus between the productive folding landscape and the aggregation landscape can 
provide information on the structures or species that partition the two competing 
reactions.  
Understanding how the primary sequence guides a protein molecule towards 
aggregation instead of productive folding and how to inhibit the former and promote the 
latter can be thought of as another goal of the protein folding field. 
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Figure 1.2: Folding and aggregation free energy landscape 
A representative combined folding (blue) and aggregation (red) free energy landscape is 
shown. Not only can polypeptide chain fold productively (blue landscape, as in Fig. 1.1) 
but it may form intermolecular interactions resulting in the formation of oligomers (left), 
amyloid fibrils (middle) or amorphous aggregates (right). This view also highlights how 
partially-folded states may serve as a link between the two landscapes (purple section).  
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Can aggregation be prevented? 
Ideally, to disrupt an aggregation reaction, we would first have a complete 
understanding of the steps in the process as well as high resolution structural information 
of the species formed at each step. Unfortunately, this information has proven to be 
challenging to obtain and such a detailed understanding of the aggregation process 
remains elusive.  
A commonly accepted, while fairly nonspecific, mechanism describing the 
process of aggregation is shown in Figure 1.349. This mechanism contains three major 
regions: a lag phase, a growth phase, and a plateau phase. The lag phase, which is 
predominantly defined by a search for a nucleating conformation, occurs after initiation 
of the reaction but prior to the formation of macromolecular aggregates50. The growth 
phase occurs when a critical concentration of the nucleating species is formed and large 
aggregates begin to rapidly form. The plateau phase is the period in which all of the 
polypeptide chains have been incorporated into aggregates and they can no longer grow. 
To further the goal of inhibiting aggregation, the lag phase is the period of most interest; 
the growth phase is past the critical point in which the reaction becomes irreversible and 
the plateau phase is defined by the behavior of the end stage aggregates. The lag phase, 
however, contains the earliest steps of the aggregation process such as misfolding and/or 
oligomerization that could be targeted to prevent the aggregation from proceeding 
further. While such a general mechanism of aggregation may be broadly applicable, the 
structural conformations formed during the process may be unique to individual proteins 
and are difficult to characterize.  
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Figure 1.3: Simple aggregation mechanism 
A simple mechanism showing aggregation as a function of time is shown. This mechanism 
is separated into three major regions: a Lag Phase (green), a Growth Phase (blue) and an 
End Phase (red). 
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A primary cause of this difficulty is the complexity involved in monitoring 
aggregation experimentally. The species populated during aggregation reactions are 
difficult to track as it involves monitoring the behavior of multiple species that make up a 
minute fraction of a highly heterogeneous sample. Furthermore, rapidly initiating 
aggregation reactions generally requires the use of powerful external stimuli such as the 
addition of large amounts of organic solvents51 or the introduction of mechanical shearing 
forces by agitating the sample52. Such harsh in vitro treatments may preferentially induce 
aggregation pathways unrelated to the aggregation pathways in vivo, making direct 
comparisons between the two processes difficult. Once aggregation has been initiated, the 
state of the reaction must be probed without perturbing the process, which is also 
problematic given the transient nature and marginal stability of many of the species 
formed during the process. This problem is exacerbated by common probes of 
aggregation, such as thioflavin T53, that are more sensitive to end stage aggregates than 
the early formed structures . The multitude of experimental challenges continues to make 
characterization of aggregation landscapes problematic, making the development of 
direct disruptors of aggregation difficult. Fortunately, there is another method by which 
we can inhibit aggregation.  
 
Preventing aggregation by enabling productive folding 
Because aggregation is intimately linked to folding, altering one process will 
inevitably affect the other. Therefore, rather than directly impede aggregation, we can 
instead facilitate productive folding. The caveat being that doing so requires a detailed 
understanding of the productive folding pathway. Fortunately, obtaining detailed folding 
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mechanisms is more thoroughly understood than doing the same for aggregation. 
Standard equilibrium and kinetic analyses can identify the major species populated 
during folding and map the pathways between these species and the native state as well 
provide information regarding the stability of each state54. The structural components of 
these species can then be determined using a wide-array of higher resolution 
techniques55–59. 
Identification of a marginally stable native state, persistent intermediate or 
unfolded states, or severely frustrated folding events all present potential sources of 
aggregation. Each potential source of aggregation also suggests possible methods for 
disrupting such aggregation. Fragile native states could be stabilized, thereby preventing 
unfolding events and reducing the opportunities for misfolding. Enhancing the rate of 
folding would decrease the time a polypeptide chain spends in the aggregation-prone 
portion of the free energy landscape. And disruption of the structures that frustrate 
folding would result in a smoother path to the native conformation. 
 The work described below will map the folding free energy landscapes of several 
proteins with links to aggregation in order to determine methods to promote productive 
folding or disrupt early steps in aggregation. 
 
MODEL SYSTEMS 
Superoxide Dismutase 1 as a model system 
The first protein examined in the work presented below is the human protein 
copper, zinc Superoxide Dismutase 1 (SOD1). SOD1 is a ubiquitously expressed enzyme 
that catalyzes the dismutase reaction of superoxide radicals into hydrogen peroxide60. 
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SOD1 is an attractive candidate for studies mapping the bridge between the folding and 
misfolding landscapes as mutant variants of SOD1 are known to aggregate and this 
aggregation is linked to the neurodegenerative disease amyotrophic lateral sclerosis 
(ALS)61.  
ALS is an invariably fatal neurodegenerative disease for which there is no cure. 
Worldwide, ALS affects ~5 in 100,000 people and the average time between initial onset 
of symptoms and death is only 2-3 years62. The symptoms of ALS are a progressive loss 
of muscle control that is caused by the death of motor neuron cells with eventual death 
caused by respiratory failure. While the exact mechanism of toxicity to motor neuron 
cells in ALS remains unclear, a hallmark of ALS and many other neurodegenerative 
diseases, is the formation of large protein-rich aggregates in affected tissues isolated from 
patients63. The observation that multiple neurodegenerative diseases share a congruent 
endpoint in which large insoluble inclusions are formed suggests protein misfolding and 
the subsequent aggregation may play a role in neurodegenerative disease pathology.  
Mutant forms of SOD1 were first linked to ALS by the Brown lab in 199361 and 
since then >180 mutations in SOD1 have been linked to ALS64. Additionally, mutations 
to other proteins such as; FUS-TLS, TDP-43, c9ORF72, PFN1, VAPB, and numerous 
others that cause ALS have been identified65. A map of the known missense mutations to 
SOD1 linked to ALS is shown along the sequence of the protein in Figure 1.4.  
SOD1 is a 32 kDa homodimeric protein in which each monomer is comprised of a 
153-residue chain that forms eight anti-parallel β-strands and two long loops. Each of the  
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Figure 1.4: Map of SOD1 mutations linked to hereditary ALS  
A map of the ALS-linked mutations is shown along the sequence of SOD1. ALS-linked 
mutations are indicated by red arrows pointing from the sequence to the known mutant 
residues. The sequence is separated into the five exons and the secondary structure 
elements are shown along the bottom of the sequence. This figure is adapted from Figure 
1.1 from the thesis, “ The coupling between folding, zinc binding, and disulfide bond status 
of human Cu, Zn superoxide dismutase” by Can Kayatekin. 
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loops in a monomer subunit binds one of two metal ion cofactors, zinc or copper. Binding 
the zinc ion stabilizes the protein66, while the copper ion is used in the catalysis 
reaction67. Each monomer subunit is further stabilized by an intramolecular disulfide 
bond. This disulfide bond is a critical component used in copper ion loading68 and is 
exceptional as disulfide bonds rarely exist in the reducing environment of the 
cytoplasm69. 
SOD1 adopts a fold similar to those seen in immunoglobulin domains that 
consists of a β-sandwich formed by two large antiparallel β-sheets, each themselves 
formed by 4 antiparallel β-strands. One sheet contains a sequence local hairpin-hairpin 
between β1-β2-β3 and a connection to the sequence distal β6, while the other sheet 
contains β4-β5 and β7-β8. β4-β5 are linked by the first of the long loops, which is 
responsible for coordinating the zinc cation and is accordingly termed the zinc-binding 
loop. β7-β8 are linked by the second long loop that is responsible for targeting the 
anionic superoxide substrate to the active site designated the electrostatic loop. β8 also 
links to Loop IV through the disulfide bridge between C146 and C57. A ribbon diagram 
and a topology map of SOD1 are shown in Figure 1.5.  
The source of mutants SOD1-linked ALS toxicity remains unclear. While a loss 
of the enzymatic function might be assumed to play a role in ALS toxicity, studies 
involving transgenic mouse models instead revealed that the toxicity arises from in a gain 
of function manner70. This result is consistent with the ALS-linked mutations being 
distributed throughout the entire sequence as shown in Figure 1.4, rather than clustered 
around the enzymatic residues. Furthermore, a loss of SOD1 enzymatic activity would 
not explain the hallmark of the disease, the formation of large insoluble aggregates. 
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Figure 1.5: Ribbon diagram and topology map of SOD1  
A ribbon diagram (top) and topology map (bottom) of SOD1 are shown. The ribbon 
diagram is adapted from PDB: 2C9V71 and shows the zinc-binding loop (green), 
electrostatic loop (purple), zinc ion (blue), copper ion (orange) and the disulfide bond 
(yellow). The same colors are used in the topology map and the eight β-strands are 
numbered and their beginning and ending residues are shown. 
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The most apparent function gained by SOD1 upon mutation is aggregation, but 
are the aggregates themselves toxic? End stage SOD1 aggregates are often described as 
amorphous, as they lack the well-defined order of fibrillar aggregates and the 
morphology of the aggregates is variable72. While the toxicity of aggregates is not fully 
understood, the amorphous aggregates are not thought to drive ALS pathology as they 
appear too late relative to the onset of symptoms to be completely responsible73,74. The 
toxicity is instead attributed to the smaller, soluble oligomers that precede the formation 
of the larger insoluble inclusions74–78. Similar mechanisms of toxicity have been proposed 
for other protein misfolding and aggregation disorders, such as Alzheimer’s79,80 and 
Parkinson’s81,82.  
The large number of mutations and their distribution throughout the sequence of 
SOD1 (Fig. 1.4) suggests that they act in a common manner to give rise to ALS. If so, 
then they likely share a common precursor that gives rise to the aggregation and toxicity. 
While some studies have identified aberrant nonnative and/or misfolded states that exist 
as branches off of the native folding landscape44,83–86, others have proposed that the 
unfolded ensemble of SOD1, a feature common to all variants, is the source of ALS-
linked aggregation47,87,88.  
While fully metalated and disulfide oxidized (SS) SOD1 dimers are 
extraordinarily stable, with a melting temp ~90° C89 and enzymatic activity maintained in 
8 M urea or 4 M guanidine hydrochloride90, this remarkable stability is only gained 
during the maturation process as metal-free (apo) disulfide reduced (2SH) SOD1 
monomers are much less stable91. The presence of ALS-linked mutations further 
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destabilizes the native state leading to significant increases in the population of the 
unfolded ensemble88,92. 
While a nascent SOD1 chain is able to fold in the absence of post-translational 
disulfide oxidation or metal ion binding, it does so exceptionally slowly. Apo-2SH-SOD1 
takes >10 seconds to fold in native conditions, making it one of the slowest folding two-
state proteins known93. The persistent lifetime of the SOD1 unfolded state coupled with 
the increase in the unfolded population of ALS-linked variants suggests that the unfolded 
state of SOD1 is the common source of aggregation in the >180 ALS-linked SOD1 
mutations. 
The work detailed below supports this suggestion by characterizing the behavior 
of the unfolded state of SOD1 and further proposes mechanisms through which these 
behaviors play a role in ALS-linked aggregation. The studies below demonstrate a unique 
role for the C-terminal region of the protein, especially the residues in β8 surrounding 
C146 from the disulfide bond, in bridging the folding and aggregation landscapes (Fig. 
1.2). Mapping the connection between the folding and aggregation of SOD1 is done with 
the hope to gain insight into the mechanism of ALS-linked aggregation and identify 
potential novel therapeutic targets.  
 
Variable Heavy Domains as a model system 
The human adaptive immune response is a complex biological system through 
which organisms challenged with foreign pathogens use those same pathogens to rapidly 
develop unique, novel protein molecules that are astonishingly specific. These protein 
molecules are antibodies. Not only do they have specificity for distinct targets, but 
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antibodies also have distinct downstream immunologic effects based on their subclass. 
The substantial malleability in both target recognition and post-binding effects is how 
human immune systems are able to correctly recognize and counter the many pathogens 
that give rise to human diseases. The assembly and secretion of mature antibody 
molecules is a tightly regulated quality control process used to ensure antibodies are not 
only selective, but also non-harmful94,95. 
Human antibodies consist of four polypeptide chains; two copies of a Heavy 
Chain (HC) and two copies of a Light Chain (LC)96. These chains connect by forming 
intermolecular disulfide bond crosslinks resulting in a macromolecular complex roughly 
shaped like the letter “Y” as shown in Figure 1.6. Each of these chains is comprised of 
several small tandem immunoglobulin domains. The nomenclature of the HC and LC are 
a result of these domains as the HC contains either 4 or 5 domains giving it a higher 
molecular weight than the LC, which contains only two domains. The HC includes a 
variable heavy domain (VH) linked to several constant heavy domains (CH1-3/4). The LC 
contains a variable light domain (VL) linked to a single constant light domain (CL).  
Each of the individual immunoglobulin domains adopts a structure termed the 
immunoglobulin-fold that is comprised of a β-sandwich formed by 2 β-sheets formed by 
7-9 β-strands with a highly conserved intramolecular disulfide bond bridging the two β-
sheets97,98. A ribbon diagram of such a domain is shown in the inset of Figure 1.6. The 
constant domains, as the name suggests, are identical across antibodies of the same 
subclass and these domains are responsible for the immune responses that occur 
downstream of antigen binding 96. The variable domains, again, as their name suggests, 
are unique to each antibody as they are the domains responsible for antigen 
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Figure 1.6: Antibody molecule illustration and ribbon diagram of a variable domain 
A cartoon diagram of an antibody is shown (left). Each chain is shown as a series of 
domains (ovals). The domains of the HC (purple) and LC (green) are labelled on the left 
side. The variable domains are shown in light colors and the constant domains are shown 
in dark colors. The intermolecular disulfide bonds are shown as orange lines. A ribbon 
diagram of a variable domain, adapted from PDB: 1N8Z99, is shown to the right. This 
diagram highlights the intramolecular disulfide bond (yellow) and CDR1 (blue), CDR2 
(red), and CDR3 (purple). 
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recognition and binding96. The specificity of the variable domains is determined by the 
sequence of three complementarity determining regions (CDR1-3). The remainder of the 
variable domain sequence is referred to as framework regions (FR). The CDRs are altered 
through the processes of V(D)J recombination100 and somatic hypermutation101. 
Recognizing the amazing therapeutic potential of antibodies, scientists have been 
developing them as treatments for human diseases for over 30 years102. Currently, 
therapeutic antibodies are the dominant portion of the biopharmaceutical marketplace103–
105 and ~60 antibodies are FDA approved as therapeutics 
(https://www.antibodysociety.org/resources/approved-antibodies/, Drugs@FDA) and 
hundreds more are under clinical development106. Due to the complicated nature of 
development, testing, and regulating human therapeutics, the time, cost and effort spent 
to develop antibody therapeutics is immense. On average, it takes 12 years and 
~$2,600,000,000 to successfully develop a new therapeutic107,108  
Until recently, using the fully evolved adaptive immune system to develop natural 
antibodies was difficult or unmanageable; as such, many current therapeutic antibodies 
are engineered or designed molecules rather than naturally evolved antibodies. Natural 
development of an antibody requires a host be challenged with the antigen target of 
interest and obvious ethical concerns prohibit the direct challenging of humans. Instead, 
animals, usually mice, are challenged and the resulting naturally develop murine 
antibodies are collected. While mouse antibodies are usually immunogenic and cannot be 
used directly as therapeutics109, the sequences of the variable domains can be used in two 
forms of therapeutics, chimeric and humanized antibodies. Chimeric antibodies are 
created by replacing the human variable domains of an antibody with the developed 
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murine variable domains110. Humanized antibody domains are created by grafting the 
CDRs from the murine domains into a FR consensus sequence generated from human 
variable domains111. Alternatively, antibody domains can be engineered completely in 
vitro by using display technology platforms to rapidly screen millions of different 
sequences for binding potential112.  
Whichever method is used during development, the resulting antibodies are not 
natural molecules. Humanized and in vitro engineered antibodies are distinctly non-
natural as they contain variable domains whose sequences were developed completely 
outside of the selection and maturation filter of natural human antibody development. In 
either case, these domains may contain “defects” that would have been screened out 
during natural maturation. Such defects would likely remain undetected, as current 
evaluation of potential antibody therapeutics is often limited to analysis of stability via 
thermal melt and measurement of binding affinity113,114. If present, such defects in the 
variable domains would be particularly problematic. Variable domain defects could 
potentially disrupt the antibody’s specificity or binding efficacy and this would result in a 
large detrimental effect on the therapeutic value and potentially introduce harmful side 
effects. 
In the work described below, three VH domains from three therapeutic antibodies 
mAb A, mAb B, and mAB C will be examined. mAb A and mAb B, when produced in 
Chinese Hamster Ovary cells, were found to have a significant population that lacked the 
intramolecular disulfide bond in the VH domain, while mAb C had no such issue 115,116. 
mAb B lacking this disulfide bond was also found to have a significant loss of binding 
affinity, demonstrating a clear role for this issue in therapeutic efficacy116. 
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mAb A is a humanized anti-CD20 antibody115. A topology map of the VH domain 
of mAb A (VHA) is shown in Figure 1.7. mAb B is a humanized anti-IgE antibody116. A 
topology map of of the VH domain of mAb B (VHB) is shown in Figure 1.8. mAb C is a 
humanized antibody that targeting HER2 and is used in the treatment of HER2 receptor 
positive breast cancer117. A topology map of of the VH domain of mAb C (VHC) is shown 
in Figure 1.9. 
These three VH domains from humanized antibodies share a high sequence 
identity (Fig. 1.10). The differences mainly arise in the residues of, or directly adjacent 
to, CDR1-3, which is to be expected as they all have distinct targets and they share a 
common framework consensus sequence118–120. Interestingly, their sequences do diverge 
in a few framework residues that are not directly adjacent to CDR1-3, but the overall 
hydrophobicity at these positions is largely conserved (Fig. 1.10).  
Despite the level of similarity between the domains, the unique behavior of VHC 
with regards to disulfide bond formation indicates that their folding pathways may not be 
conserved, unlike behavior seen in other protein families 121–123. Mapping the folding 
mechanisms of these domains will not only provide insight into what gives rise to the 
varying levels of disulfide bond formation in these domains, but will also provide a 
unique opportunity to explore how human-directed development efforts may impact 
folding mechanisms when the natural filters of evolution and antibody maturation are 
removed. It may also provide insights into potential methods for re-engineering future  
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Figure 1.7: Topology map of VHA domain  
A topology map of the VH domain of mAB A is shown. The β-strands are numbered and 
their beginning and ending residues are shown. The intramolecular disulfide bond is shown 
by the orange dotted line and CDR1-3 (blue, red, and purple, respectively) are shown.  
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Figure 1.8: Topology map of VHB domain 
A topology map of the VH domain of mAB B is shown. The β-strands are numbered and 
their beginning and ending residues are shown. The intramolecular disulfide bond is shown 
by the orange dotted line and CDR1-3 (blue, red, and purple, respectively) are shown. 
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Figure 1.9: Topology map of VHC domain 
A topology map of the VH domain of mAB C is shown. The β-strands are numbered and 
their beginning and ending residues are shown. The intramolecular disulfide bond is shown 
by the orange dotted line and CDR1-3 (blue, red, and purple, respectively) are shown. 
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Figure 1.10: Sequence alignment of mAb A, B, and C VH domains 
A sequence alignment map of the VH domains from mAB A, B, and C is shown. The 
alignment was performed using the abYsis software124. The exact residues are not shown 
to preserve intellectual property of Genentech Inc. Identical residues are indicated with a 
dot. Relative hydrophobicity of residues is indicated by the color scale with red-most 
hydrophobic to blue-most polar. The conserved cysteines that for the disulfide bond are 
shown in yellow. Gaps in the sequences are indicated by --. The residues are numbered 
according to the Kabat numbering system125.  
 
  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
VHA ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
VHB ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
VHC ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 35A 36 37 38 39
VHA ● ● ● ● ● ● ● ● ● -- ● ● ● ●
VHB ● ● ● ● ● ● ● ● ● ● ● ● ●
VHC ● ● ● ● ● ● ● ● ● -- ● ● ● ●
40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58
VHA ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
VHB ● ● ● ● ● ● ● ● ● ● ● -- ● ●
VHC ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78
VHA ● ● ● ● ● ● ● ● ● ● ● ● ● ●
VHB ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
VHC ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95
VHA ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
VHB ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
VHC ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
96 97 98 99 100 100A 100B 100C 100D 100E 101 102 103 104 105 106 107 108 109 110
VHA ● ● ● ● ● ● ● ● ● ● ●
VHB ● -- ● ● ● ● ● ● ● ● ●
VHC -- -- ● ● ● ● ● ● ● ● ●
111 112 113
VHA ● ● ●
VHB ● ● ●
VHC ● ● ●
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therapeutic sequences to favor fully oxidized disulfide bonds and simple folding 
behaviors. 
 
SCOPE OF THESIS  
The scope of this thesis is to describe the folding free energy landscapes of 
several β-sandwich proteins that have direct links to human disease and medicine. While 
each protein is a unique background in which to study the competition between 
aggregation and folding, the goal is to identify general mechanisms or early events in 
protein misfolding and/or aggregation that could present novel targets for therapeutics to 
disrupt disease-linked aggregation processes. Doing so might also allow early and rapid 
identification of therapeutic molecules that may be susceptible to misfolding and 
aggregation.  
Chapter 2 will present work examining the behavior of short peptides of the 
SOD1 sequence in solution with potential implications in the neurodegenerative disease 
ALS. Using a version of maximum entropy modeling to analyze the time-resolved 
lifetime decays of a series of FRET donor-only and donor-acceptor labeled peptides 
revealed that only the peptide corresponding to the C-terminal region of SOD1 forms 
local nonnative structure. Surprisingly, truncation of the polar residues at the N-terminus 
and mutation of a hydrophobic residue at the C-terminus of this peptide both disrupted 
the nonnative structure, indicating that both regions are involved its formation. We 
propose that this nonnative state could be a precursor to the pathological aggregation of 
SOD1 and may present a target for therapeutic interventions. 
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Chapter 3 is an overview of how, through modulation of solvent viscosity, the 
folding and unfolding of disulfide-reduced monomeric SOD1 was limited by internal 
chain friction, but the same phenomenon was not observed in the disulfide-intact 
monomer of SOD1. While the use of an established isostability method suggested the 
presence of such internal friction, the errors in the linear regression typically used to 
determine the existence and magnitude of internal friction were large. To address this, we 
developed an alternative method to globally analyze the kinetic data to obtain the 
magnitude of the chain friction. The presence of internal chain friction only in the 
reduced form of SOD1 suggests that the regions near the disulfide bond, Loop IV and β8, 
drive the chain friction. It is possible that the friction arises from these regions sample 
nonnative structures, which must be disrupted before proper folding can occur and that 
the formation of the disulfide bond disrupts these structures. 
In Chapter 4, preliminary work detailing the folding mechanisms of VH domains 
of three therapeutic antibodies and the important role played by the disulfide bond in 
driving these processes is examined. Despite the three domains being developed using 
similar consensus framework sequence, they fold through mechanisms of varying 
complexities. Interestingly, the observed complexities in these mechanisms were 
disrupted by reduction of the disulfide bond but this also produced significant issues with 
aggregation. The observation of complexities in the folding of these therapeutic 
molecules demonstrates that thorough biophysical analyses performed early in the 
development process may provide more criteria to use in the selection of potential 
therapeutics. Furthermore, these results may help guide future antibody design and 
engineering endeavors.  
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Chapter 5 summarizes the results of these studies and discusses them in the 
broader context of understanding the competition between folding, misfolding and 
aggregation as well as describing the future directions of these projects. The insights 
gained from these works provide a basis for future work focused on the development of 
therapeutic approaches acting through the disruption of early states populated in disease-
linked aggregation. The same framework of thought applied to the selection and design of 
therapeutics may result in the selection and development of treatments with simple, well-
characterized biophysical behaviors. Thorough examination of the biophysics of 
molecules related to disease will help create new therapeutics and improve those that 
currently exist. 
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Chapter II – Nonnative structure in the unfolded ensemble 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is adapted from an article currently in press: 
 
Nonnative structure in a peptide model of the unfolded state of superoxide dismutase 1 
(SOD1): Implications for ALS-linked aggregation   
 
Noah R. Cohen, Jill A. Zitzewitz, Osman Bilsel, and C. Robert Matthews  
Journal of Biological Chemistry, 2019 
doi: 10.1074/jbc.RA119.008765 
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INTRODUCTION 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder affecting 
motor neuron cells, where it causes progressive loss of muscle control and eventual 
death62,126. Patients afflicted with ALS often only survive 2-3 years after the initial onset 
of symptoms, demonstrating the rapid and invariably fatal effects of the disease. The 
majority of all ALS cases occur in a sporadic nature, and only a small fraction (~10%) are 
linked to heritable mutations62,126. The first of the familial ALS proteins to be discovered 
was Cu, Zn superoxide dismutase 1(SOD1)61. SOD1 is a homodimeric protein in which 
each monomer is comprised of a 153-residue chain that adopts a β-sandwich fold. Each 
monomer is stabilized by an intramolecular disulfide bridge and contains two metal ion 
cofactors, zinc and copper (Fig. 2.1A). The zinc ion has been shown to stabilize the protein, 
while the copper ion is crucial to the enzymatic activity of SOD1127. Intriguingly, >170 
mutations in the sod1 gene linked to ALS are located throughout the sequence of the protein 
(http://alsod.iop.kcl.ac.uk/)64.  
Although the mechanism of pathogenesis by mutations in SOD1 is poorly 
understood, a hallmark of ALS and many other neurodegenerative diseases is the 
observation of large protein-rich aggregates in affected tissues128. The observation of a 
common endpoint of large cellular inclusions has given rise to the hypothesis that ALS 
may result from toxicity related to protein misfolding and subsequent aggregation129,130. 
While the disulfide-intact, metal-bound SOD1 dimer is remarkably stable and resistant to 
aggregation131, mutations are known to destabilize the native dimer and increase the 
populations of folded and unfolded forms of the monomeric protein that may nucleate 
aggregation92,132–135. Several studies have suggested specific structures for such misfolded 
 46 
 
Figure 2.1: SOD1 ribbon diagram and peptide design  
A, Ribbon diagram of Cu,Zn SOD1, adapted from PDB: 2C9V, is shown71. The bound 
copper and zinc metal cofactors are shown as orange and grey spheres, and the internal 
disulfide bond is shown in yellow. The zinc binding and electrostatic loops are shown in 
green and red, respectively. B, Each of the examined SOD1 peptides is mapped onto the 
topology diagram as a unique color in the top left. A sketch demonstrating how the FRET 
donors-acceptor pairs were placed at the termini of the peptides is shown on the top right. 
The exact residue length of each peptide is shown along a linear map of the SOD1 structure 
using the same colors as the topology map above. The colors associated with each peptide 
are carried forward.  
A
B
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 monomers and nonnative dimers44,83,84,136. However, the large number of ALS-linked 
SOD1 mutations and, in particular, their distribution throughout the sequence, motivated 
us to propose a general explanation for the aggregation phenomenon. 
Work from our lab on ALS variants of SOD1 have revealed that: (A) the 
destabilization of the metal-free native dimeric state increases the populations of both the 
folded and unfolded forms of the monomer132, (B) the unfolded form of the disulfide-
reduced monomer is favored at physiological temperatures88, and (C) the lifetime of the 
unfolded monomer, prior to folding, is remarkably long, >10 s137. These observations 
support the hypothesis that the unfolded form of SOD1, after synthesis on the ribosome 
and prior to folding and maturation, is the source of aggregation in motor neurons. Also 
supporting this hypothesis are the results of Lang et al.87 which showed that the lag time 
prior to fibrillar aggregation of SOD1 in vitro was linked to the magnitude of population 
of SOD1 in the unfolded state. Increasing the unfolded state population with denaturant led 
to a decrease in the lag time and increase in the fibrillation rate, implicating the unfolded 
state as a common precursor for the aggregation of ALS variants. This work was expanded 
upon by comparison of the calculated in vitro aggregation rates to the in vivo aggregation 
rates determined for several mouse models47. The good agreement argues for a common 
mechanism of aggregation in vitro and in vivo. 
Eisenberg and colleagues have found that two heptapeptides derived from SOD1, 
one from the loop between β6-β7 and the other from β8, are capable of forming cross-beta 
structures that could serve as precursors to large scale aggregates138. The concept that 
discrete segments of SOD1 could serve as critical nucleation sites is further supported by 
the results of proteolytic digestion experiments on in vitro and in vivo derived aggregates 
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of SOD1139. Three different continuous segments of SOD1, spanning β1-β3 (an 
interlocking pair of β-hairpins), β5-β6 (a β-hairpin) and Loop VII-β8 (a region that lacks 
native self-contacts) were shown to be strongly protected against proteolysis in vitro; in 
vivo, only the Loop VII-β8 segment was protected. 
Building upon these results, we investigated the propensity for spontaneous 
collapse in five peptides that span the entire sequence of SOD1. We found that only the 
peptide corresponding to the Loop VII-β8 segment of SOD1 was capable of adopting a 
compact structure. Surprisingly, the compact form is separated from the expanded form by 
an energy barrier that gives rise to an apparent two-state behavior when exposed to 
increasing concentrations of denaturant, rather than a gradual swelling of the segment as 
would be expected for a randomly collapsed state. We propose that the Loop VII-β8 
segment as a promising candidate to be the primary nucleation site for the aggregation of 
ALS variants of SOD1 in ALS.  
 
RESULTS 
Strategy 
We adopted the time-resolved FRET (trFRET) technique to measure the 
compaction of a set of peptides spanning the SOD1 sequence: the β1-β3 peptide (residues 
1-36), the β4 peptide (residues 32-57), the Loop IV peptide (residues 58-86), the β5-β7 
peptide (residues 87-120) and the Loop VII-β8 peptide (residues 121-153) (Fig. 2.1B). 
Three of these peptides were chosen on the basis of their resistance to proteolysis in in vitro 
and in vivo aggregates139, supposing that these segments might be capable of nucleating 
aggregation reactions. The remaining two peptides, spanning residues 32-57 and 58-86, 
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completed the set spanning the entire sequence. The peptides were purchased in pairs such 
that one of the pair contained only a single tryptophan (Trp) donor residue at or near one 
terminus, serving as the donor-only peptide (DO). The second member of the pair 
contained a tryptophan residue as well as a 5-((2-aminoethyl)amino)naphthalene-1-
sulfonic acid (EDANS) moiety conjugated to a glutamic acid residue at the other terminus, 
serving as the donor-acceptor peptide (DA). The Förster distance for Trp-EDANS is ~22 
Å and is suitable for measuring the dimensions of peptides of these lengths.  
 
FRET Efficiency from time-resolved fluorescence data 
To test the state of compaction for each peptide we observed the excited state decay 
for each DO and DA pair as a function of denaturant using time-correlated single photon 
counting as previously described140. We used Maximum Entropy Modeling (MEM)141,142 
to fit these decays to rate distributions using the equation: 
"#$/#&(() = +,(-.)/012∙45-.             (Eq. 2.1) 
where "#$/#& is the observed excited state decay for the DO or DA peptide, ,(-.) is the 
distribution of excited-state decay rates, -. is the donor decay rate constant and is also the 
inverse of the donor lifetime, 1/τ, and ( is the time. From these distributions, we determined 
the quantum yield weighted average lifetime of the Trp,	9:;, using the equation: 
9:; = 	Σ=>=9=?Σ=α=9= 																											(Eq. 2.2) 
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where > is the amplitude associated with a distinct lifetime, 9, from the rate distribution. 
We then determined the quantum yield weighted averaged trFRET efficiency for each 
peptide and using the equation: 
 A4BCDEF = 1 − 9#&:;9#$:; 																						(Eq. 2.3) 
Denaturant dependence of average trFRET efficiency 
The quantum yield weighted average trFRET efficiency for the set of five peptides 
spanning the SOD1 sequence is plotted as a function of denaturant concentration in the top 
panel of Figure 2.2. Strikingly, the trFRET efficiencies the Loop IV and Loop VII-β8 
peptides were dependent on the urea concentration; the trFRET efficiencies of the 
remaining peptides were independent of the urea concentration. The trFRET efficiencies 
of both the Loop IV and Loop VII-β8 peptides decreased with increasing urea 
concentration. The decrease for the Loop VII-β8 peptide was distinctly nonlinear and larger 
than that for the linear decrease for the Loop IV peptide. The expansion of the Loop VII-
β8 peptide with denaturant is independent of the peptide concentration over the range from 
2 to 20 μM, eliminating peptide-peptide interactions as an explanation for its behavior.  
Noting that the β5-β6 segment, residues 82-102, forms a short β-hairpin in the 
native structure and was also found to be protected from proteolysis in in vitro 
aggregates139, we examined the trFRET response of a peptide corresponding to this hairpin 
to increasingly denaturing environments (Fig. 2.3). This peptide was also found to be 
insensitive to denaturant. 
As an independent test of the formation of structure in these peptides, we measured 
the far-UV CD spectra of each in the absence and presence of denaturant (Fig. 2.4). With 
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Figure 2.2: trFRET efficiency of SOD1 peptides as a function of denaturant  
The quantum yield weighted average trFRET efficiencies for each of the five SOD1 
peptides are shown as a function of denaturant (top, colors as in Figure 2.1B), and trend 
lines are shown to demonstrate the linearity or nonlinearity of the FRET change for each 
peptide. The FRET efficiencies for the Loop VII-β8 peptide (red) and the I149T (maroon) 
and truncated (pink) variants are shown as a function of denaturant (bottom) and trend lines 
are shown to demonstrate the linearity or nonlinearity of the FRET change for each peptide. 
The data points represent the average of ≥3 separate experimental runs, and the error bars 
are the standard deviation thereof.  
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Figure 2.3: trFRET efficiency of the β5-β6 peptide as a function of denaturant  
The quantum yield weighted average trFRET efficiency for the β5-β6 peptide is shown as 
a function of denaturant (grey circles) and trend lines for this and the other examined 
peptides are shown for reference (colors as in Figure 2.2). The data points represent the 
average of 3 separate experimental runs and the error bars are the standard deviation 
thereof. 
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Figure 2.4: CD spectra of the examined peptides  
The CD spectra of each peptide (colors as in Figures 2.2, 2.3), in aqueous (solid lines), 
mildly denaturing (dashed lines), and strongly denaturing (dotted lines) conditions are 
shown. Each panel is labeled with the peptide examined in a corner. 
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the exception of the Loop VII-β8, the spectra in aqueous and denaturing conditions are 
coincident. We conclude that none of the other peptides formed detectable secondary 
structure. 
The Loop VII-β8 peptide is unique in that the loop segment is of low complexity 
and polar, typical of an intrinsically disordered protein143, while the β8 sequence is almost 
entirely nonpolar. To test the involvement of these distinctly different sequences at the 
termini of this peptide in its trFRET efficiency, we examined the behavior of two variants. 
One replaces isoleucine 149 in the β8 region with a threonine, an ALS-linked mutation that 
eliminates protection against proteolysis for in vitro aggregates of SOD1139. The other 
variant truncates five residues, EKADD, from the N-terminus (Fig 2.5). We found that the 
trFRET efficiency for both variants in water is similar to that of the WT peptide in highly 
denaturing conditions (Fig. 2.2, bottom). The trFRET efficiency for the I149T variant is 
independent of denaturant concentration while that of the truncated variant experiences a 
small linear decrease, similar to the behavior of the Loop IV peptide. Surprisingly, these 
results show that both the polar N- and nonpolar C-termini of the Loop VII-β8 peptide are 
involved in stabilizing the compact form of the peptide.  
 
Gradual swelling or discrete unfolding? 
The sensitivity of the trFRET efficiency to denaturant for the Loop IV and Loop 
VII-β8 peptides could reflect a gradual expansion from a nonspecific collapsed state144–146 
or a two-state-like expansion from a discrete compact state to an expanded unfolded 
state147. To resolve this issue, we utilized a two-dimensional form of Maximum Entropy 
Modeling (2DMEM)140. 2DMEM is unbiased in that it makes no assumptions regarding 
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Figure 2.5: Loop VII-β8 peptide variant diagram 
Diagram demonstrating the changes made to the Loop VII-β8 peptide to form the examined 
variants is shown at the top. How the primary sequence was changed in these variants is 
shown at the bottom. Colors used as in Figure 2.2.  
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the number of subpopulations or their lifetimes and allows for the possibility that each 
could have a distinct distance distribution140. By analyzing our time-resolved fluorescence 
data with MEM, we can distinguish states that are resolved on the nanosecond time-scale. 
In 2DMEM, the raw excited state decays of the DO and DA peptides are globally fit using 
a 2D rate distribution matrix of donor decay, kd and energy transfer, kET, rate constants 
using Eq. 2.1 and the following: 
"#&(() = I,(-., -EF)/0(12K1LM)∙45-.5-EF 		(Eq. 2.4) 
There are two striking features in the results of the 2DMEM analysis of the Loop 
VII-β8 peptide (Fig. 2.6A). First there are multiple values of kd and kET operative in the 
excited state decay. The three donor decay rate constants at 0.3, 1, and 8 ns-1 are 
characteristic of tryptophan148, but only the slower two are FRET competent. The presence 
of both low and high FRET states with kET values of <1 and >1 ns-1, respectively, indicate 
the presence of both expanded and compact states of the peptide. As the urea concentration 
increases, the population of the compact, high FRET state decreases while the population 
of the expanded, low FRET state increases in a concerted manner (Fig. 2.6B-3E). The 
results show that the change in trFRET efficiency for the Loop VII-β8 peptide reflects a 
two-state-like process between compact and expanded states separated by a kinetic barrier 
that is long relative to the nanosecond timescale of Trp excited-state decay. A denaturant-
induced expansion of a randomly collapsed peptide would have produced a continuous 
shift of the high FRET state to the low FRET state. As a control, 2DMEM analysis of the 
β1-β3 peptide data in the absence of denaturant reveals only an expanded, low FRET state 
(Fig. 2.6F). The observation of a single donor decay rate constant for this 
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Figure 2.6: 2DMEM distributions for the Loop VII-β8 peptide as a function of 
denaturant  
A-E, The concentrations of urea examined are shown in the lower right corners of each 
panel, and the upper right corner of each panel is labeled with the examined peptide. The 
amplitude of the distributions in B-E was normalized to the amplitude in A to emphasize 
the change in response to denaturant. F, The 2DMEM distribution for the β1-β3 peptide in 
the absence of denaturant is shown for reference. The diagonal white reference lines are 
marked with the FRET efficiency along each line. The yellow arrows indicate the 
amplitude associated with extended conformations, and the cyan arrows indicate the 
amplitude associated with compact conformations. 
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peptide suggests that sequence differences in proximity to the indole side chain influence 
the rotamer distribution, which is often offered as an explanation for the multiple lifetimes 
for Trp149,150. The β1-β3 peptide is unique among the examined peptides as the Trp donor 
is not at a terminus of the peptide, and the presence of residues before and after the Trp 
may give rise to the single lifetime distribution. 
We also used 2DMEM analysis to examine the behavior of the Loop VII-β8 peptide 
variants in water (Fig. 2.7A-C). Neither the truncated nor the I149T variants were found to 
populate a compact, high FRET state, and both had trFRET efficiencies comparable to that 
for the WT Loop VII-β8 peptide under strongly denaturing conditions. We conclude that 
both the polar residues in the electrostatic loop and the nonpolar residues of β8 are involved 
in the formation of the compact state. The absence of a compact state for the truncated 
variant eliminates the possibility that other, intervening segments of the Loop VII-β8 
peptide are involved in the compact state and indicates that the donor-acceptor probes do 
not drive the formation of the compact state. 
We also used 2DMEM analysis to examine the Loop IV peptide in water and found 
that it does not populate a compact, high FRET state distinct from the expanded low FRET 
state (Fig. 2.7D). The continuous intensity from the low to high FRET region reflects the 
breadth of the conformational ensemble sampled by this peptide, and the small shift in 
response to increasing amounts denaturant (Fig. 2.8) is evidence that the change in trFRET 
observed in Fig. 2.2 reflects a gradual expansion of the molecule.  
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Figure 2.7: The 2DMEM distributions for the Loop VII-β8 peptide variants 
A-D, The concentrations of urea examined are shown in the lower right corners of each 
panel, and the upper right corner of each panel is labeled with the examined peptide. The 
diagonal white reference lines are marked with the FRET efficiency along each line. The 
yellow arrows indicate the amplitude associated with extended conformations, and the cyan 
arrows indicate the amplitude associated with compact conformations.  
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Figure 2.8: 2DMEM distributions for the Loop IV peptide as a function of denaturant  
A-D, The concentrations of urea examined are shown in the lower right corners of each 
panel and the upper right corner of each panel is labeled with the examined peptide. The 
diagonal white reference lines are marked with the FRET efficiency along each line. The 
yellow arrows indicate the amplitude associated with extended conformations and the cyan 
arrows indicate the amplitude associated with compact conformations. 
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Dimensional analysis of the compact state for the Loop VII-β8 peptide in water 
The energy transfer rate constant, kET, axis of the 2DMEM distributions (Figs. 2.7A 
and 2.8A) can be transformed into end-to-end distances through the Förster equation (see 
Materials and Methods). The transformation yields a matrix that provides the lifetime 
distribution of the donor residue, the end-to-end distance distribution for the peptide, as 
well as information about the donor lifetimes present in each ensemble of states. The result 
for the WT Loop VII-β8 peptide in the absence of denaturant is shown as a three-
dimensional surface in Fig. 2.9, and the lifetime distribution of the Trp donor and the 
distance distribution are projected along the XZ and YZ axes, respectively.  
The lifetime distribution contains three peaks at ~0.3, ~1, and ~7 nanoseconds, in 
good agreement with typical complex lifetime distributions of Trp148. The distance 
distribution shows a significant fraction of the population is compact with an end-to-end 
distance (REED) of ~14 Å that is only apparent from the two slower lifetimes. The 
conformational ensemble of the expanded state is very broad, with an estimated REED >30 
Å. For reference, the expected REED for a random coil of 35 residues is ~45 Å151.  
 
DISCUSSION 
The C-terminus of SOD1 forms a compact state 
Our trFRET data show that only the Loop VII-β8 peptide from SOD1 is capable of 
forming a compact thermodynamic state in water. The concerted transition from a compact 
to an expanded state with urea implies an intervening energy barrier; the sensitivity to urea 
reflects the burial of surface area from solvent, and the presence of comparable populations 
of the compact and expanded states are consistent with marginal stability, that is, ∆G0≈0  
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Figure 2.9: Three-dimensional surface of the transformed 2DMEM distribution for the 
WT Loop VII-β8 peptide in the absence of denaturant  
The two-dimensional Trp lifetime distribution and the end-to-end distance distribution are 
shown as projections along the XZ and YZ axes, respectively.   
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kcal/mol. The sensitivity of the compact state to the truncation of five residues (EKAAD) 
from the N-terminus and the I149T mutation near the C-terminus demonstrates their mutual 
involvement in its structure. These same segments are not in contact in the native 
conformation (Fig. 2.1), suggesting that nonnative interactions are responsible for its 
formation. Interestingly, a peptide spanning residues 131-153 of SOD1 was used to 
develop an antibody recognizing misfolded, but not native, SOD1, consistent with our 
interpretation152,153.   
 One possibility for the nonnative structure is the formation of a β-hairpin by the 
nonpolar residues that form β8 and a pair of glycines at positions 27 and 30 that could 
enable a turn (see Materials and Methods for the sequence). A small β-hairpin would 
explain the far-UV CD spectra observed for the Loop VII-β8 peptide in water (Fig. 2.4). 
This hairpin could serve to sequester the hydrophobic side chains from solvent and serve 
as a platform to interact with the polar residues at the N-terminus of the peptide.   
 
Prior studies on the folding free energy surface of SOD1 
Classic thermodynamic and kinetic studies of the folding of the monomeric chain 
of SOD1 have concluded that the reaction is well described by a two-state process, with a 
high barrier between the native and unfolded states93. However, ensemble measurements 
may miss complexities that could appear in the folding of an individual chain. Woodside 
and colleagues have examined the folding free energy surface of a single molecule of SOD1 
when subjected to a constant force exerted on the N- and C-termini44. They found a 
complex set of partially-unfolded states that reflect the progressive unraveling of the β-
sandwich architecture by the loss of individual β-strands. The initial step was the rupture 
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of the β8 edge strand, and the final steps involved the disruption of structure in the β1-β2-
β3 set of interlocking β-hairpins in one face of the sandwich and β4 in the opposing face. 
A contrasting view of the folding free energy surface of SOD1 in water at the individual 
amino acid level was obtained by hydrogen exchange (HDX) NMR spectroscopy154. HDX-
NMR is exquisitely sensitive to the presence of high-energy, partially-unfolded states of 
the sort predicted by the pulling experiments. The HDX-NMR results were consistent with 
a native basin defined by an intact β-sandwich, several of whose β-strands frayed at their 
termini. The majority of the main chain amide hydrogens in the β-strands exchanged in the 
unfolded state, i.e., not on the native side of the barrier to unfolding. There was no evidence 
for the partially-folded structures detected by the pulling experiment. Consistent with these 
results are those of kinetic folding studies of SOD1 by CD spectroscopy that did not detect 
the formation of secondary structure prior to the rate-limiting step in folding137, i.e., on the 
unfolded side of the barrier to the native state. With the exception of the C-terminal peptide, 
the failure to detect compaction in peptides modeled after obvious elements of substructure 
in SOD1 in our trFRET experiments are in agreement with the HDX-NMR and CD studies. 
In other work, the partially-unfolded states observed by pulling experiments have been 
found to depend on the location of the tethers to exert the pulling force155,156. It remains to 
be seen how to relate the energy surfaces generated by pulling experiments on a single 
molecule with ensemble measurements using hydrogen exchange or chemical 
denaturation. 
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A mechanism for the aggregation of SOD1 by the Loop VII-β8 segment 
The >10 s lifetime of the unfolded state of SOD193, prior to folding and maturation, 
would promote the formation of the compact structure at the C-terminus. A conceptual 
model for the mechanism by which this nonnative structure could lead to aggregation is 
shown in Figure 2.10. The intrinsically long lifetime of the unfolded state combined with 
its being favored under physiological conditions by ALS mutations88, provides an 
environment in which the intramolecular interactions in a single chain are replaced by 
intermolecular interaction between pairs of chains. These dimers could then progressively 
add chains to form a collection of soluble oligomers. The high local concentration of SOD1 
chains in these oligomers would enhance the subsequent maturation to fibrils or amorphous 
aggregates. The observation that only the C-terminus is protected against proteolysis in 
aggregates extracted from mouse motor neurons suggests that this region is the primary 
driver of aggregation. 
We used the aggregation prediction algorithms Aggrescan157, WALTZ158, and 
TANGO159 to examine which of the peptides would be predicted to be prone to aggregation 
(Fig. 2.11). While two peptides, β4 and Loop IV, were predicted to have little or no 
aggregation prone stretches, the other peptides, β1-β3 and β5-β7 and Loop VII-β8, were 
predicted to have several regions that could be prone to aggregation. Interestingly, the only 
peptide where the three different algorithms show consensus is the Loop VII-β8 peptide 
and it is also the most hydrophobic region of the SOD1 sequence160. 
 This mechanism does not account for the properties of the I149T mutation. I149T 
disrupts the compact structure in the C-terminus and eliminates protection against 
proteolysis for in vitro aggregates139; however, it causes ALS. The observation that the  
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Figure 2.10: A model for the role of the compact Loop VII-β8 region in ALS-linked 
SOD1 aggregation 
In this model, the C-terminal region (black line) is able to form the compact state, Uc, while 
the rest of the polypeptide chain remains unfolded (red dotted line). Once the compact state 
has formed, it can meet other compact states and form lower order, soluble oligomers. 
These oligomers could then further recruit polypeptide chains until insoluble aggregates, 
either fibril-like or amorphous, are formed. 
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Figure 2.11: Aggregation propensity of the SOD1 peptides 
The aggregation propensity score for each of the examined peptides determined by the 
three algorithms, Aggrescan (Green), WALTZ (blue) and TANGO (red) is shown in the 
first five panels. The final panel shows the Kyte-Doolittle hydrophobicity along the SOD1 
sequence (pink). The mean (dark grey), one standard deviation (grey), and two standard 
deviation (light grey) lines are shown for reference. The most hydrophobic region, 
corresponding to part of the β8 sequence, is colored in dark red.  
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β1-β3 and the β5-β6 segments are protected against proteolysis for in vitro aggregates of 
I149T shows that secondary nucleation sites come into play when the primary site is 
destabilized. Further support for alternative nucleation sites is the existence of the ALS-
linked variants L126X, G127X, G141X, and C146X which truncate varying amounts of 
the C-terminus of SOD164. The L126X variant was also shown to form in vitro aggregates 
with protection patterns similar to I149T139. The existence of multiple pathways through 
which SOD1 can aggregate may also explain how different ALS-inked mutants give rise 
to morphologically distinct aggregates72. 
Another noteworthy element of the mechanism we propose is that it is not 
dependent upon the presence of an ALS-linked SOD1 mutation. The long lifetime of the 
unfolded chain, >10 sec, would provide an opportunity for the C-terminal region to sample 
the nonnative structure even in the WT-SOD1 background. The chain containing this 
nonnative structure could then be recognized by other misfolded protein partners, thereby 
providing an explanation for the recent observation of aggregated WT-SOD1 in tissue from 
patients with pathological ALS mutations in other genes72.  
 
Implications for therapeutic targets 
The swap of intramolecular interactions for intermolecular interactions between C-
terminal segments of unfolded SOD1 is the key step in the progression of events leading 
to soluble oligomers and macroscopic aggregation (Fig. 2.10). One therapeutic approach 
would be to screen for small molecules that preferentially stabilize the intramolecular, 
compact state and favor productive folding to the native dimer. Most ALS variants of 
SOD1 are extremely stable in their fully mature dimeric states161,162. An alternative 
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approach, shown to be effective in non-human primates163, would be to knockdown the 
expression of SOD1 with siRNAs and, thereby, slow the bimolecular steps crucial to the 
formation of soluble oligomers and aggregates. While not offering a cure for this tragic 
disease, these approaches or others might delay the onset and/or slow the progression of 
ALS. 
 
MATERIALS AND METHODS 
Peptide Design and Preparation 
The peptides spanning the SOD1 sequence used in the FRET experiments were 
ordered form New England Peptide Inc., where the proper molecular weight was checked 
by mass spectrometry and the purity was ensured to be >95% by HPLC. The sequences 
corresponding to the donor-only peptides follow:  
 
β1-β3 peptide: TKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIK 
β4 peptide: WGSIKGLTEGLHGFHVHEFGDNTAGC 
Loop IV peptide: WTSAGPHFNPLSRKHGGPKDEERHVGDLGN 
β5-β7 peptide: VTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHW 
Loop VII-β8 peptide: EKADDLGKGGNEESTKTGNAGSRLACGVIGIAQW 
I149T peptide: EKADDLGKGGNEESTKTGNAGSRLACGVTGIAQW 
 
Truncated peptide: LGKGGNEESTKTGNAGSRLACGVTGIAQW 
β5-β6 peptide: GDLGNVTADKDGVADVSIEDSW 
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The donor-acceptor peptides are comprised of the same sequences with a Glu-EDANS 
moiety at the terminus opposite the Trp residue.  
Small amounts (~1-2 mg) of the peptides were weighed out and resuspended in our 
experimental buffer: 20 mM HEPES, 1mM EDTAN, and 1 mM TCEP at pH=7.2. Each 
peptide stock was filtered through a polyethersulfone 0.22 μm filter and the concentrations 
were then determined using the 280 absorbance peak from the Trp donor (ε280 = 5690 M-
1cm-1) using a Cary 100-UV/Vis spectrophotometer. For the CD analysis, the same method 
was used, but the buffer used was 10 mM KPi, 1mM EDTA, and 1 mM TCEP at pH=7.2. 
 
CD Spectroscopy 
All CD measurements were performed with a Jasco-810 spectropolarimeter (Jasco 
Inc., Easton, MD) using a water-cooled Peltier unit. The spectra of the SOD1 peptides 
from 190 to 260 nm were monitored using a synthetic fused silica 0.1-cm path-length 
cuvette at a scan rate of 20 nm per min and an 8 second response time. The same methods 
were used to collect denatured spectra of the peptides, yet from only 215-260 nm to avoid 
scattering.  
 
Time-Resolved FRET Measurements 
The excitation was provided by the tripled output of a Ti:sapphire laser at 3.8 MHz 
repetition rate as previously described140,147. Excitation power was kept at several hundred 
μWatts at 292 nm. Counting rates in the detector channel were limited to 1×105 counts per 
second. A 357 nm 40 nm wide bandpass filter (Semrock, Rochester, NY) was used to select 
the Trp emission. 
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The samples were prepared from stocks of peptide in buffer and peptide in ≥ 6 M 
urea and mixed precisely using a Hamilton Microlab 500 titrator and in-house software. 
Equilibrium measurements were performed by interfacing a home-built autosampler 
running custom LabVIEW software (available at www.osmanbilsel.net) to the lifetime 
instrument. Each sample in a 96-well microplate was brought into a flow cell (1mm×1mm) 
using a Hamilton Microlab 560 dual syringe pump and flowed in an oscillating pattern at 
a flow rate of 10 μL/s during data collection. Doing so reduced continuous exposure of the 
sample to the beam to <1 s and minimized photobleaching. An N-acetyl tryptophanamide 
(NATA) control was obtained prior to each titration in order to obtain relative quantum 
yields for all of the samples.  
 
Maximum Entropy Modeling 
Kumar et al.164 have shown that MEM can recover the distribution of decay rates 
from time-resolved data. To determine the trFRET values as a function of denaturant (Fig. 
2.2 and 2.3), the excited-state decay of the Trp donor in the DO and DA peptides at each 
urea concentration were fit using Eq. 2.1. These distributions were used to calculate the 
quantum-yield weighted averaged lifetimes using Eq. 2.2 from which the trFRET 
efficiencies were calculated using Eq. 2.3.  
The 2DMEM used to further analyze the time-resolved data used Eq. 2.1 and Eq. 
2.4 to simultaneously fit the excited-state decays of the DO and DA samples, respectively. 
The fitting of all the MEM data was done with in-house software coded in LabVIEW 
(National Instruments). The p(kd,kET) distributions were represented by 50×50 grids of 
rates in logarithmic rate space. No scaling of the DO and DA traces was used in the global 
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fitting except in cases where a concentration difference was known to be present. 
Additional terms accounting for scattered light and infinite time offsets were included in 
these analyses, but these were negligible and exclusion of these terms did not affect the 
resulting distributions.  
These distributions were converted into efficiency histograms and distance 
distributions using another in-house software package that applies a quantum-yield 
correction to the R0 of the donor-acceptor pair. The output of this software was then plotted 
in Figure 2.9 as a three-dimensional surface of REED, kd, and normalized Amplitude using 
the online open source software plot.ly. Two-dimensional projections of the REED vs 
normalized amplitude and kd vs normalized amplitude distributions were also plotted along 
their respective axes. 
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INTRODUCTION 
The proper folding of polypeptides has becomes an area of intense interest related 
to human health, as protein misfolding and subsequent aggregation are associated with 
numerous neurological diseases9. Aggregates containing an antioxidant protein, Cu, Zn 
superoxide dismutase (SOD1), were identified in the brain and spinal cord tissues of 
patients suffering from amyotrophic lateral sclerosis (ALS), an invariably fatal disease 
caused by the atrophy of motor neurons61. Subsequently, 160 mutations at 88 positions 
have been discovered in the sod1 gene in patients suffering from ALS 
(http://alsod.iop.kcl.ac.uk/), making SOD1 variants responsible for a large fraction of 
familial ALS64. 
SOD1 is a 153-residue homodimeric β-sandwich protein containing eight anti-
parallel β-strands in each monomer (Fig. 3.1). Each subunit binds a structural zinc and a 
catalytic copper ion and contains an intramolecular disulfide bond between C57 in Loop 
IV following β4 and C146 in β8. Loop IV binds the zinc ion, while Loop VII, the 
electrostatic loop, serves to support Loop IV and guides the anionic substrate to the redox 
active copper ion. The mature protein is remarkably stable and soluble in its native 
dimeric, metal bound, disulfide-intact form. As such, loss of metals, reduction of the 
disulfide-bond, and dissociation of the dimer, have been considered necessary to induce 
aggregation88,132,165–168. Consequently, attention has turned to the disulfide-reduced 
monomer as a potential driver of the aggregation of SOD187,88,134,135,162,169.  
Although the folded and unfolded forms of reduced and oxidized versions of a 
stable monomeric form, mSOD1170, dominate the denaturant-induced unfolding profiles, 
minor partially-folded states could represent a source of aggregation-prone  
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Figure 3.1: Ribbon diagram of mSOD1 
The view of mSOD1 along each of the β-sheets is shown, adapted from PDB: 2C9V71. The 
eight β-strands are labeled and the zinc-binding and electrostatic loops are shown in blue 
and purple, respectively. The disulfide bond between C57-C146 is shown in yellow.  
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material44,84,85,88,132,136. Another source of aggregation-prone material might be found on 
the unfolded side of the rate-limiting barrier in the form of local condensations of the 
chain. By sampling the variety of conformational species present in the unfolded state 
ensemble, the formation of non-native contacts might be able to interfere with the 
productive folding of SOD1. These putative nonnative intramolecular interactions, which 
could be replaced by intermolecular interactions that nucleate aggregation, might be 
detected by their propensity to slow folding below the diffusion limit171,172.  
A general approach towards seeking these nonnative states of SOD1 is to 
introduce small molecule polyols into the solvent. Glycerol, glucose and other 
kosmotropes increase the free energy differences between folded and unfolded states by 
mechanisms that have been ascribed to preferential hydration of nonpolar surfaces or a 
decrease in the solubility of peptide bonds173–175. This strategy has been utilized to reveal 
an intermediate in the folding reaction of barstar and offers an opportunity to highlight 
partially-folded states in SOD1176. Through their capacity to increase the solvent 
viscosity, glycerol and glucose also provide a kinetic test for nonnative structures that can 
limit the rates of the folding reaction. Diffusional processes involved in folding are 
expected to slow with increasing viscosity and the existence of intramolecular chain 
friction can be determined by a less than unitary dependence of the relative folding rate 
constant on the relative solvent viscosity175–177.  
We found that reduced and oxidized monomeric SOD1 closely adhere to a two-
state mechanism in glycerol and glucose when examined by both equilibrium and kinetic 
methods. Using a novel method to globally fit the kinetic data, we found that the folding 
and unfolding reactions of only the disulfide-reduced protein were partially limited by 
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internal chain friction. The simple diffusional processes observed for its oxidized 
counterpart suggest that the internal friction experienced by reduced SOD1 involves the 
formation of structure involving one or both of the segments containing the C57 and 
C146 partners in the disulfide bond.  
 
MATERIALS AND METHODS 
SOD1 monomer model and expression/purification 
The SOD1 monomer variant, mSOD1, has a pair of nonpolar to polar mutations at 
the dimer interface, F50E and G51E, that prevents dimerization170. The two cysteines at 
positions 6 and 111 were replaced with alanine and serine, respectively, to eliminate 
disulfide scrambling with the C57-C146 disulfide bond in the unfolded state. 
Recombinant metal-free SS-mSOD1 was expressed and purified according to the 
procedure previously described132, and 2SH-mSOD1 was created by incubation with 1 
mM of TCEP for several hours at room temperature93. 
 
Thermodynamic and Kinetic CD experiments 
CD spectroscopy was performed on a Jasco-810 spectropolarimeter (Jasco Inc., 
Easton, MD) equipped with a water-cooled Peltier temperature control system. The 
equilibrium Gdn-HCl induced unfolding transitions were monitored from 215-240 nm in 
a 0.2 cm path length synthetic fused silica cuvette using a scan rate of 20 nm per min and 
a response time of 8 s. Manual-mixing kinetic folding and unfolding reactions, with a 
deadtime of 3-5 seconds, were monitored at 230 nm with a response time of 1-2 s in a 1 
cm cuvette. Gdn-HCl concentrations were determined by refractive index on a Leica 
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Mark II refractometer. The protein concentrations were 15 µM for equilibrium 
experiments and 5-10 µM for kinetic experiments. The buffer conditions were 20 mM 
HEPES, 1mM EDTA for SS-mAS-SOD1 experiments and 20 mM HEPES, 1mM EDTA, 
and 1 mM TCEP for 2SH-mAS-SOD1 experiments. The temperature was 20° C for all 
experiments. The data analyses were performed with an in-house software Savuka 
available online at: https://osmanbilsel.com/. 
 
Solvent viscosity measurements 
The solvent viscosity at each polyol concentration was determined using a 
Gilmont falling ball viscometer (Thermo Scientific). The time of travel was measured 10 
times for each sample and was repeated a minimum of 2 times with fresh sample 
preparations. All buffers were filtered and degassed prior to the experiment. 
 
RESULTS 
Equilibrium studies 
To test for partially-folded states in mSOD1 we employed circular dichroism 
(CD) spectroscopy to monitor the influence of glycerol and glucose on the folding free 
energy surface revealed by chemical denaturation. Both metal-free disulfide oxidized-
mSOD1 (SS-mSOD1) and metal-free disulfide reduced-mSOD1 (2SH-mSOD1) 
exhibited increased stability with increasing concentrations of glycerol, as evidenced by 
the shift of the midpoint of the equilibrium titration, Cm, to higher concentrations of 
guanidine hydrochloride (Gdn-HCl)(Fig. 3.2, left panels). A similar trend was observed 
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Figure 3.2: Polyol dependence of equilibrium titrations  
The equilibrium titration of SS-mSOD1 (top) and 2SH-mSOD1 (bottom) at increasing 
concentrations of glycerol (circles) and glucose (squares), monitored by CD spectroscopy 
at 230 nm, are shown with a two-state fit to the data (solid lines). SS-mSOD1: glycerol 
percent by volume (top left): 0% (white), 10% (red), 16% (orange), 24% (yellow), 28% 
(green), 30% (blue) and 32% (purple). SS-mSOD1: glucose percent by volume (top right): 
0% (white), 11% (dark red), 17% (dark orange), 20% (dark green), 24% (dark blue) and 
26% (dark purple). 2SH-mSOD1: glycerol percent by volume (bottom-left) and glucose 
percent by volume (bottom-right) follow the same color scheme.   
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for glucose (Fig. 3.2, right panels), demonstrating that this phenomenon is not specific to 
the choice of kosmotrope.  
The data were fit to a two-state model assuming a linear dependence of the free 
energy of folding on the denaturant concentration137, and quantitative estimates of the 
free energy of folding are provided in Table 3.1. Over the range of cosolvents explored, 
0% to 32% by volume, the unfolding transitions for both forms of mSOD1 were well-
described by two-state models, and the stabilities were found to increase by ~2-fold 
(Tables 3.1, 3.2). Interestingly, the trend is reversed for the denaturant dependence of the 
free energy of folding, the meq-values, that decrease by ~25% over this range in glucose 
or glycerol concentrations for both SS-mSOD1 and 2SH-mSOD1 (Tables 3.1, 3.2). 
Although the decrease in the meq-value could reflect the presence of partially-folded 
states whose population is increased by the kosmotropes, companion kinetic studies of 
the folding reactions offer an alternative explanation (see below). 
 
Kinetic studies 
As an orthogonal test for the presence of partially-folded states, we performed 
kinetic folding experiments on SS-mSOD1 and 2SH-mSOD1. The unfolding and 
refolding reactions for metal-free SS-mSOD1 and 2SH-mSOD1 were monitored by CD 
spectroscopy at 230 nm. The resulting kinetic traces were well-fit by single exponential 
functions that provided the apparent rate constant, k, and its reciprocal, the relaxation 
time, τ. The excellent agreement between the ellipticities at the beginning of both 
unfolding and refolding reactions and the estimated ellipticities of the native and 
unfolded states under the same conditions, eliminates the possibility of partially-folded  
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Table 3.1: Thermodynamic Parameters  
for the folding reaction of SS-mSOD1 
Solvent Condition ΔG°eq meq Cm 
0% Cosolvent -4.10 ± 0.30 4.98 ± 0.36 0.82 ± 0.08 
10% Glycerol -4.86 ± 0.22 4.56 ± 0.23 1.07 ± 0.07 
16% Glycerol -5.40 ± 0.10 4.25 ± 0.08 1.27 ± 0.03 
24% Glycerol -5.73 ± 0.18 3.76 ± 0.12 1.53 ± 0.07 
28% Glycerol -7.04 ± 0.27 4.26 ± 0.17 1.65 ± 0.09 
30% Glycerol -7.42 ± 0.59 4.35 ± 0.36 1.71 ± 0.19 
32% Glycerol -7.64 ± 0.18 4.15 ± 0.10 1.84 ± 0.06 
11% Glucose -5.08 ± 0.33 4.41 ± 0.29 1.15 ± 0.11 
17% Glucose -5.58 ± 0.38 4.04 ± 0.28 1.38 ± 0.13 
20% Glucose -6.54 ± 0.88 4.36 ± 0.56 1.51 ± 0.28 
24% Glucose -7.09 ± 0.64 4.28 ± 0.41 1.66 ± 0.22 
26% Glucose -8.26 ± 0.22 4.68 ± 0.13 1.77 ± 0.07 
 
The thermodynamic parameters obtained from fitting the Gdn-HCl titrations of SS-mSOD1 
are shown for each cosolvent concentration examined. The equilibrium denaturant 
dependence, meq, is shown in kcal mol-1 [D]-1 where [D] is the molar concentration of 
denaturant. The units of the folding free energy, ΔG°Eq, are in kcal mol-1. The midpoint, 
Cm, of each titration is shown as the [Gdn-HCl] (M).  
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Table 3.2: Thermodynamic Parameters 
for the folding reaction of 2SH-mSOD1 
Solvent Condition ΔG°eq meq Cm 
0% Cosolvent -2.04 ± 0.05 5.92 ± 0.12 0.34 ± 0.01 
10% Glycerol -2.96 ± 0.20 5.28 ± 0.31 0.56 ± 0.05 
16% Glycerol -3.57 ± 0.11 4.65 ± 0.14 0.77 ± 0.03 
24% Glycerol -4.23 ± 0.18 4.42 ± 0.18 0.96 ± 0.06 
28% Glycerol -4.85 ± 0.25 4.24 ± 0.21 1.14 ± 0.08 
32% Glycerol -5.56 ± 0.11 4.40 ± 0.08 1.26 ± 0.03 
11% Glucose -3.11 ± 0.10 5.02 ± 0.15 0.62 ± 0.03 
17% Glucose -3.42 ± 0.10 4.30 ± 0.12 0.80 ± 0.03 
20% Glucose -4.04 ± 0.28 4.61 ± 0.29 0.87 ± 0.08 
24% Glucose -4.56 ± 0.21 4.21 ± 0.21 1.08 ± 0.07 
26% Glucose -5.15 ± 0.16 3.59 ± 0.11 1.43 ± 0.06 
 
The thermodynamic parameters obtained from fitting the Gdn-HCl titrations of 2SH-
mSOD1 are shown for each cosolvent concentration examined. The equilibrium denaturant 
dependence, meq, is shown in kcal mol-1 [D]-1 where [D] is the molar concentration of 
denaturant. The units of the folding free energy, ΔG°Eq, are in kcal mol-1. The midpoint, 
Cm, of each titration is shown as the [Gdn-HCl] (M).  
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species with significant amounts of secondary structure forming within the deadtime of 
the experiment (Fig. 3.3). The chevron plots, the observed relaxation times as a function 
of final denaturant concentration, are shown in Figure 3.4. These data demonstrate that 
increasing concentrations of glycerol and glucose stabilize the native state of the protein 
by decreasing the refolding times and increasing the unfolding relaxation times. The net 
effect of these changes moves the maximum relaxation time, where ku = kf, to 
progressively higher concentrations of denaturant, concordant with the Cm values from 
the equilibrium studies.  
The chevron data were well described by a simple two-state kinetic model linking 
the native and unfolded states. The predicted free energy differences in the absence of 
denaturant between the folded and unfolded states were calculated from ∆G0 = -RT ln 
(ku/kf), where the rate constants in the absence of denaturant were obtained by linear 
extrapolations of the unfolding and refolding legs of the chevron plot to determine τf/τu, 
the reciprocal of kf/ku. The meq-value can also be determined by summing the absolute 
values of the mu‡- and mf‡-values, the slopes of the two legs of the chevron plot137. The 
resulting values are listed in Tables 3.3 and 3.4. The agreement between the kinetic and 
equilibrium estimates of stability, the meq-values, and the Cm values for both SS-mSOD1 
and 2SH-mSOD1 over the range of kosmotrope concentrations examined (Fig. 3.5), and 
the absence of burst-phases (Fig. 3.3) rule out the presence of partially-folded states as an 
explanation for the reduction of meq-values at increasing kosmotrope concentrations.  
It is noteworthy that the denaturant dependence of the unfolding and refolding 
relaxation times (Tables 3.3, 3.4), the mu‡- and mf‡- values, for SS-mSOD1 and 2SH-
mSOD1, vary with glycerol and glucose concentration in a fashion that leaves their  
 85 
 
Figure 3.3: Burst phase analysis for the unfolding and refolding of SS- and 2SH-
mSOD1 
A comparison of the initial ellipticities in kinetic experiments (dark circles) are shown with 
the respective equilibrium titrations (light circles) for SS-mSOD1 (top, blue circles) and 
2SH-mSOD1 (bottom, red circles). The coincidences of the initial ellipticities for unfolding 
jumps to high denaturant concentration with the extrapolated native baselines and the 
refolding jumps with the extrapolated unfolded baselines shows no loss in secondary 
structure or collapse in the dead-time of the mixing experiments.  
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Figure 3.4: Polyol dependence of the folding kinetics 
Chevron plots at increasing concentrations of glycerol (circles) and glucose (squares) of 
SS-mSOD1 and 2SH-mSOD1, obtained by CD spectroscopy at 230 nm, are shown with a 
two-state fit to the data (solid lines). Color schemes as in Figure 3.2. 
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Table 3.3: Kinetic Parameters for the folding reaction of SS-mSOD1 
Solvent 
Condition τf mf
‡ τu mu‡ ΔGeq‡ meq‡ Cm η Tβ 
0% Cosolvent 41.4 ± 2.62 3.93 ± 0.13 (78.4 ± 5.48) × 103 -1.70 ± 0.02 -4.39 ± 0.06 5.63 ± 0.13 0.78 ± 0.02 1.01 ± 0.05 0.70 ± 0.03 
10% Glycerol 15.6 ± 0.42 3.57 ± 0.11 (13.3 ± 1.60) × 104 -1.55 ± 0.03 -5.27 ± 0.09 5.12 ± 0.12 1.03 ± 0.03 1.30 ± 0.11 0.70 ± 0.03 
16% Glycerol 9.99 ± 0.03 3.27 ± 0.11 (2.33 ± 0.42) × 105 -1.51 ± 0.04 -5.85 ± 0.12 4.78 ± 0.12 1.22 ± 0.04 1.66 ± 0.06 0.69 ± 0.03 
24% Glycerol 4.20 ± 0.57 2.99 ± 0.10 (8.55 ± 1.55) × 105 -1.54 ± 0.04 -7.11 ± 0.13 4.54 ± 0.11 1.57 ± 0.05 2.34 ± 0.09 0.66 ± 0.03 
28% Glycerol 2.44 ± 0.18 3.15 ± 0.05 (11.7 ± 2.75) × 105 -1.51 ± 0.04 -7.61 ± 0.14 4.66 ± 0.07 1.63 ± 0.04 2.65 ± 0.13 0.68 ± 0.01 
30% Glycerol 1.75 ± 0.29 3.13 ± 0.11 (10.7 ± 1.65) × 105 -1.41 ± 0.03 -7.76 ± 0.13 4.54 ± 0.11 1.71 ± 0.05 2.87 ± 0.06 0.69 ± 0.03 
32% Glycerol 1.48 ± 0.17 3.11 ± 0.08 (12.5 ± 2.50) × 105 -1.37 ± 0.04 -7.94 ± 0.13 4.48 ± 0.09 1.77 ± 0.05 3.19 ± 0.07 0.70 ± 0.02 
11% Glucose 9.99 ± 0.96 3.50 ± 0.10 (13.5 ± 1.74) × 104 -1.51 ± 0.03 -5.53 ± 0.10 5.02 ± 0.11 1.10 ± 0.03 1.34 ± 0.06 0.70 ± 0.03 
17% Glucose 7.08 ± 0.69 3.09 ± 0.07 (26.2 ± 5.10) ×104 -1.47 ± 0.04 -6.12 ± 0.13 4.56 ± 0.08 1.34 ± 0.04 1.74 ± 0.08 0.68 ± 0.02 
20% Glucose 3.49 ± 0.42 3.26 ± 0.10 (51.8 ± 6.70) × 104 -1.51 ± 0.03 -6.93 ± 0.10 4.77 ± 0.10 1.45 ± 0.04 1.90 ± 0.05 0.68 ± 0.03 
24% Glucose 2.99 ± 0.53 2.99 ± 0.15 (8.79 ± 1.71) × 105 -1.53 ± 0.04 -7.33 ± 0.15 4.52 ± 0.15 1.62 ± 0.06 2.26 ± 0.08 0.66 ± 0.04 
26% Glucose 1.88 ± 0.34 3.08 ± 0.13 (8.92 ± 1.84) ×105 -1.41 ± 0.04 -7.61 ± 0.16 4.49 ± 0.14 1.69 ± 0.06 2.50 ± 0.19 0.69 ± 0.04 
 
The parameters obtained from fitting the chevron plots of SS-mSOD1 are shown for each cosolvent concentration examined. The 
extrapolated refolding, τf, and unfolding, τu, relaxation times and the errors of the fit to the chevron plots (Fig. 3.3) are shown in seconds. 
The fits and errors for the refolding, mf‡, and unfolding, mu‡, portions of the chevron plots are shown in kcal mol-1 [D]-1. The free energies 
of folding, ΔG‡eq, were calculated from the kinetic data and are shown in kcal mol-1. The denaturant dependence of the free energy of 
folding, meq‡, calculated as, meq‡= mf‡- mu‡ is also shown in kcal mol-1 [D]-1. The midpoint, Cm, of each titration is shown in [Gdn-HCl] 
(M). The viscosity of each buffer condition is shown in centipoises and was calculated using a Gilmont falling ball viscometer. The 
average and standard deviation of 10 trials is shown. The Tanford beta, Tβ, for each viscogen concentration was calculated to be Tβ = 
mf‡/( mf‡- mu‡). 
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Table 3.4: Kinetic Parameters for the folding reaction of 2SH-mSOD1 
Solvent 
Condition τf mf
‡ τu mu‡ ΔGeq‡ meq‡ Cm η Tβ 
0% Cosolvent 133 ± 7.49 4.59 ± 0.17 (8.48 ± 0.33) × 103 -1.43 ± 0.02 -2.42 ± 0.04 6.02 ± 0.17 0.40 ± 0.01 1.01 ± 0.05 0.70 ± 0.03 
10% Glycerol 35.9 ± 3.18 3.94 ± 0.13 (1.69 ± 1.63) × 104 -1.37 ± 0.03 -3.58 ± 0.08 5.31 ± 0.13 0.67 ± 0.02 1.30 ± 0.11 0.70 ± 0.03 
16% Glycerol 15.6 ± 1.79 4.13 ± 0.16 (2.12 ± 0.92) × 104 -1.27 ± 0.11 -4.20 ± 0.27 5.40 ± 0.19 0.78 ± 0.06 1.66 ± 0.06 0.69 ± 0.03 
24% Glycerol 7.42 ± 0.81 3.66 ± 0.11 (4.13 ± 0.79) × 104 -1.19 ± 0.04 -5.02 ± 0.13 4.85 ± 0.12 1.04 ± 0.04 2.34 ± 0.09 0.66 ± 0.03 
28% Glycerol 4.57 ± 0.75 3.52 ± 0.20 (5.21 ± 0.54) × 104 -1.13 ± 0.03 -5.44 ± 0.11 4.65 ± 0.20 1.17 ± 0.06 2.65 ± 0.13 0.68 ± 0.01 
32% Glycerol 3.66 ± 0.34 3.37 ± 0.07 (7.75 ± 1.32) × 104 -1.09 ± 0.04 -5.80 ± 0.11 4.45 ± 0.08 1.30 ± 0.03 3.19 ± 0.07 0.70 ± 0.02 
11% Glucose 25.6 ± 2.86 4.05 ± 0.15 (1.42 ± 0.24) × 104 -1.31 ± 0.05 -3.68 ± 0.12 5.36 ± 0.16 0.69 ± 0.03 1.34 ± 0.06 0.70 ± 0.03 
17% Glucose 11.6 ± 1.37 3.86 ± 0.13 (3.05 ± 0.47) × 104 -1.28 ± 0.04 -4.58 ± 0.11 5.14 ± 0.14 0.89 ± 0.03 1.74 ± 0.08 0.68 ± 0.02 
20% Glucose 7.24 ± 0.53 3.42 ± 0.06 (4.17 ± 0.38) × 104 -1.24 ± 0.02 -5.04 ± 0.07 4.66 ± 0.07 1.08 ± 0.02 1.90 ± 0.05 0.68 ± 0.03 
24% Glucose 3.84 ± 0.28 3.50 ± 0.06 (8.33 ± 1.11) × 104 -1.25 ± 0.03 -5.81 ± 0.09 4.75 ± 0.06 1.22 ± 0.02 2.26 ± 0.08 0.66 ± 0.04 
26% Glucose 3.19 ± 0.46 3.42 ± 0.10 (1.16 ± 0.31) × 105 -1.19 ± 0.06 -6.11 ± 0.18 4.60 ± 0.12 1.33 ± 0.05 2.50 ± 0.19 0.69 ± 0.04 
The parameters obtained from fitting the chevron plots of 2SH-mSOD1 are shown for each cosolvent concentration examined. The 
extrapolated refolding, τf, and unfolding, τu, relaxation times and the errors of the fit to the chevron plots (Fig. 3.3) are shown in seconds. 
The fits and errors for the refolding, mf‡, and unfolding, mu‡, portions of the chevron plots are shown in kcal mol-1 [D]-1. The free energies 
of folding, ΔG‡eq, were calculated from the kinetic data and are shown in kcal mol-1. The denaturant dependence of the free energy of 
folding, meq‡, calculated as, meq‡= mf‡- mu‡ is also shown in kcal mol-1 [D]-1. The midpoint, Cm, of each titration is shown in [Gdn-HCl] 
(M). The viscosity of each buffer condition is shown in centipoises and was calculated using a Gilmont falling ball viscometer. The 
average and standard deviation of 10 trials is shown. The Tanford beta, Tβ, for each viscogen concentration was calculated to be Tβ = 
mf‡/( mf‡- mu‡).
 89 
 
Figure 3.5: The thermodynamic parameters of SS-mSOD1 and 2SH-mSOD1 are 
comparable when measured by kinetics or equilibrium 
 
The folding free energies, (ΔG°eq, top), the denaturant dependence of the free energy of 
folding, (meq-value, middle), and the midpoints (Cm, bottom) from the equilibrium (light 
colors) or kinetic (dark colors) experiments are in good agreement for both SS-mSOD1 
(blue and purple, left) and 2SH-mSOD1 (red and orange, right). This agreement is observed 
regardless of whether the cosolvent used was glycerol (blue and red colors) or glucose 
(purple and orange colors). The ΔG°eq are shown in kcal mol-1. The meq-values are shown 
in kcal mol-1 [D]-1. The Cm are shown in [Gdn-HCl] (M).   
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Tanford beta, Tβ, values unchanged across the range of glycerol and glucose 
concentrations explored (Fig. 3.6). Tβ reflects the fraction of the buried surface area in the 
transition state ensemble (TSE) relative to the buried surface area in the native state and 
is calculated as Tβ = mf‡/( mf‡- mu‡)178. The Tβ values for SS-mSOD1 and 2SH-mSOD1 
are ~0.68 ± 0.02 and ~0.75 ± 0.01 kcal mol-1 M-1, respectively, and are independent of 
kosmotrope concentration. The robust positions of the TSEs in terms of buried surface 
area for both oxidized and reduced mSOD1 demonstrate that these additives have a 
common but proportional effect on the structures and the free energies of the TSE and the 
unfolded state. The reduction in the meq-value in the presence of kosmotropes (Tables 
3.1-3.4) is, therefore, a consequence of the solvent composition and does not reflect the 
presence of an additional thermodynamic state. This conclusion is consistent with a 
previous study that observed the compaction of the unfolded state of SNase in response to 
viscogen179. The consistently higher meq-value (Tables 3.1-3.4) and the greater Tβ value 
for 2SH-mSOD1 (Fig. 3.6) likely reflect the increased solvent exposure of side chains 
and backbone in an unfolded form that is not constrained by the disulfide crosslink.  
 
Viscosity Dependence of Folding 
Although the presence of glycerol or glucose did not reveal partially-folded states 
for SS-mSOD1 or 2SH-mSOD1, these additives offer another probe of the folding 
reactions. Glycerol and glucose also act to substantially increase the solvent viscosity, 
providing a test for intramolecular friction in limiting diffusive folding reactions. 
Intramolecular chain friction could be exchanged for intermolecular interactions that 
could nucleate aggregation in SOD1. 
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Figure 3.6: Tanford β is unaffected by a change in viscosity 
The Tanford β value of each cosolvent is shown as a function of the resultant viscosity. 
The Tanford β values of SS- and 2SH-mSOD1 in buffer (blue and orange diamond, 
respectively) are shown. Neither SS-mSOD1 (blue) nor 2SH-mSOD1 (red) experiences a 
change in the Tanford β value when exposed to increasing concentrations of glycerol 
(circles) or glucose (squares).   
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The rate constants of diffusion-limited reactions are expected to vary linearly with 
solvent viscosity, accordingly to the Kramer’s formalism180–186:  
! = 	1% 	= &' + ) exp -−∆01‡34 5 														67. 3.1 
where k is the rate constant, τ is the corresponding relaxation time, C is an adjustable 
parameter, η is the viscosity of the solvent, σ is the internal friction, ΔG0‡ is the intrinsic 
barrier height under standard conditions, R is the gas constant and T is the absolute 
temperature. Thus, in the absence of significant internal friction, the folding rate constant 
should vary inversely with the solvent viscosity, k  1/η187,188. A less than unitary 
dependence of the observed rate constant on the solvent viscosity, i.e., a nonzero value 
for σ, has been taken as evidence for chain friction in limiting the folding of three helix 
bundle spectrin domains189–192, a photolyzed cytochrome c193, an ultrafast folding 
protein194, and unfolded and intrinsically disordered proteins195–197. Because viscogens 
significantly alter the thermodynamic properties, an isostability approach, in which the 
refolding and unfolding rate constants were interpolated under strongly refolding and 
unfolding conditions, is typically employed176,180,198. This approach, however, does not 
account for the observed dependence of the mf‡ and mu‡-values for SOD1 on the viscogen 
concentration (Tables 3.1-3.4).  
To address this issue, we developed a method of globally fitting the chevron data 
by introducing parameters that describe the viscogen dependence of the thermodynamic 
and kinetic properties of the folding reaction. As noted above, viscogens alter both the 
stability and the meq-value of SS- and 2SH-mSOD1. When plotted as a function of 
viscogen concentration, we observed that ∆G0, meq‡, mf‡ and mu‡ all vary linearly as a 
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function of viscogen concentration (Figs. 3.7 and 3.8). Interestingly, the viscogen 
dependence of each parameter was unique to each of the examined viscogens and the 
linear fits of the data show that glucose has a 2-3 fold stronger effect on the stability and 
m-values than glycerol. Adding terms to Eq. 3.1 to describe the effect of viscogen on the 
m-values and ∆G0 results in the following equation: 
 
!:;< 	= 	 &=' + )= exp >?@=‡ + A=‡[CDEF]H[IJK] − @L=‡ [CDEF]34 M
+ &N' + )N exp -?@N‡ + AN‡[CDEF]H[IJK] + @LN‡ [CDEF]34 5 								67. 3.2 
 
where [Visc] and [Den] are molar concentrations of viscogen and denaturant, !:;< is the 
observed rate constant at that viscogen and denaturant concentration, &=/N are adjustable 
parameters, mf‡ and mu‡ represent the denaturant dependence of the rate constants, Af‡ and Au‡ are the viscogen dependence of mf‡ and mu‡, mvf‡ and mvu‡ represent the viscogen 
dependence of the transition state free energy, η is the solvent viscosity, and σf and σu are 
the chain friction terms for folding and unfolding. Note that the viscogen dependence 
terms Af‡, Au‡, mvf‡ and mvu‡ are unique for the specific viscogens, while the other terms 
are universal parameters. A key assumption in this approach is the independent effects of 
denaturant and viscogen on the experimentally measured viscosity. A previous study 
supports this assumption in the range of Gdn-HCl and glucose concentrations used in our 
study199. 
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Figure 3.7: Viscogen dependence of ∆G0eq for SS-mSOD1 and 2SH-mSOD1 
The ∆G0eq of SS-mSOD1 (blue) and 2SH-mSOD1 (red) as a function of either glycerol (M) 
(light circles) or glucose (M) (dark squares) is shown along with linear fits of the data (solid 
and dashed for glycerol and glucose, respectively). The ∆G0eq in the absence of viscogen 
is shown as a diamond for both SS-mSOD1 and 2SH-mSOD1.   
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Figure 3.8: Viscogen dependence of m-values for SS-mSOD1 and 2SH-mSOD1 
The meq (top), mf‡ (middle), and mu‡ (bottom) are shown for SS-mSOD1 (blue) and 2SH-
mSOD1 (red) as a function of either glycerol (M) (light circles) or glucose (M) (dark 
squares) along with linear fits to the data (solid and dashed for glycerol and glucose, 
respectively). The units of meq, mf‡, and mu‡ are in kcal mol-1 [D]-1. The m-values in the 
absence of viscogen are shown for SS-mSOD1 and 2SH-mSOD1 as blue and orange 
diamonds, respectively. meq was calculated as mf‡-mu‡.  
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Global fits of the chevron data for both SS-mSOD1 and 2SH-mSOD1 to Eq. 3.2 
provided an excellent description of the results (Fig. 3.9). Supporting the validity of the 
analysis is the excellent agreement between (1) the results of the individual linear 
regression values for terms Af‡, Au‡, mvf‡, and mvu‡ and those obtained from the global fit 
(Table 3.5) and (2) the estimates of the friction coefficients for the unfolding and 
refolding reactions in the presence of glucose and glycerol (Table 3.6). A global fit of the 
combined glucose and glycerol data sets, subjected to a rigorous error analysis (Fig. 3.10) 
finds the folding and unfolding friction coefficients for SS-mSOD1 are σf = 0.07 ± 0.09 
and σu = 0.00 ± 0.01. SS-mSOD1 experiences neither friction-limited folding nor 
unfolding. By distinct contrast, the friction coefficients for 2SH-mSOD1 are σf = 1.02 ± 
0.24 and σu = 0.87 ± 0.13. We conclude that 2SH-mSOD1 experiences internal chain 
friction during both folding and unfolding reactions, slowing access to the productive 
TSE from both the native and the unfolded states of 2SH-mSOD1.  
 
DISCUSSION 
The introduction of glucose and glycerol to the solvent for mSOD1 enabled two 
distinct tests for partially-folded states that might serve to nucleate the aggregation 
reaction known to be a hallmark of SOD1 variants that cause ALS. Although a 
substantial perturbation of the folding free energy surface by a pair of kosmotropes did 
not reveal the presence of a distinct, high-energy thermodynamic state for either SS-
mSOD1 or 2SH-mSOD1, the accompanying increase in solvent viscosity revealed 
friction-limited folding and unfolding for the disulfide-reduced protein. The contrasting 
behavior of SS-mSOD1 pinpoints unique roles for one or both of the segments adjacent  
 97 
 
Figure 3.9: Global fit of folding kinetics 
Global fits using Eq 3.2 are shown for SS-mSOD1 (top) and 2SH-mSOD1 (bottom) in 
Glycerol (left) and glucose (right). Colors as in Figure 3.2.  
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The parameters from fitting the viscogen dependence of the kinetic parameters to linear regressions are compared to the 
parameters obtained with the global fitting method. The units of αf/u‡ are shown in kcal mol-1 [D]-1 [Visc]-1 where [D] and [Visc] 
are the molar concentrations of denaturant and viscogen. The units of the mvf‡-, mvu‡-, and mveq‡-values are kcal mol-1 [Visc]-1. 
The mveq‡-value for the global fit parameters was calculated as, mveq‡ = mvf‡- mvu‡. 
 
Table 3.5: Parameters extracted from the linear regression of the viscogen dependence 
 are in excellent agreement with those obtained from the global fit 
 Glycerol Glucose 
SS-mSOD1 !f‡ !u‡ mvf‡ mvu‡ mveq‡ !f‡ !u‡ mvf‡ mvu‡ mveq‡ 
Linear Fit -0.20 ± 0.02 0.06 ± 0.01 N/A N/A -0.88 ± 0.05 -0.65 ± 0.08 0.17 ± 0.04 N/A N/A -2.26 ± 0.16 
Global Fit -0.25 ± 0.02 0.07 ± 0.01 -0.54 ± 0.01 0.23 ± 0.02 -0.77 ± 0.02 -0.72 ± 0.05 0.17 ± 0.02 -1.41 ± 0.04 0.65 ± 0.05 -2.06 ± 0.06 
           
2SH-mSOD1 !f‡ !u‡ mvf‡ mvu‡ mveq‡ !f‡ !u‡ mvf‡ mvu‡ mveq‡ 
Linear Fit -0.27 ± 0.03 0.08 ± 0.00 N/A N/A -0.77 ± 0.01 -0.85 ± 0.08 0.15 ± 0.01 N/A N/A -2.58 ± 0.13 
Global Fit -0.20 ± 0.01 0.09 ± 0.00 -0.58 ± 0.01 0.16 ± 0.01 -0.74 ± 0.01 -0.54 ± 0.04 0.21 ± 0.02 -1.70 ± 0.04 0.58 ± 0.05 -2.28 ± 0.06 
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Table 3.6: Comparison of σf/u from  
glycerol-only, glucose-only, and global fits 
 glycerol glucose global 
 σf σu σf σu σf σu 
SS-mSOD1 0.06 ± 0.04 0.00 ± 0.03 0.06 ± 0.04 0.00 ± 0.03 0.07 ± 0.09 0.00 ± 0.03 
2SH-mSOD1 0.97 ± 0.07 0.88 ± 0.04 0.86 ± 0.05 1.09 ± 0.09 1.02 ± 0.24 0.87 ± 0.13 
 
The value of σ obtained using Eq 3.2 to fit the glycerol-only, glucose-only, and global data 
sets. σ is in units of cP. 
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Figure 3.10: Rigorous error analysis of σf and σu for SS-mSOD1 and 2SH-mSOD1 
The rigorous error analysis of σf (light lines) and σu (dark lines) is shown for SS-mSOD1 
(blue) and 2SH-mSOD1 (red). The y-axis shows the probability of obtaining a better fit to 
the data as a function of the σ-values along the x-axis. The grey line denotes a p=0.68, 
which corresponds to a single standard deviation in the σ-value.   
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to C57 and C146, i.e., loop IV and β8, in introducing the chain friction that slows the 
refolding and unfolding reactions. 
 
Molecular mechanisms of internal chain friction in proteins 
Despite the observation of friction-limited folding in several proteins, the 
molecular mechanisms responsible for friction remain a subject of active discussion. 
Experimental observation of friction in spectrin domains has been attributed to nonnative 
docking of helices189. MD simulations on short peptides suggested that internal friction 
was due to isomerization of local torsional angels200 and was closely linked to the !-
helical propensity of the protein201,202. This interpretation is consistent with the 
observation of internal friction in several fast folding proteins193,194,203,204. However, this 
explanation may not account for the observation of internal friction in unfolded 
proteins195,197 or the experimental observation of helical proteins lacking internal 
friction177,186,198. This hypothesis would not obviously apply to SOD1, a β-sandwich 
protein.  
A clue to the source of friction in 2SH-mSOD1 is its absence in its oxidized 
counterpart, SS-mSOD1. The implication is that the disulfide bond effectively blocks the 
intramolecular interactions that cause friction. Examination of the sequences adjacent to 
the C57 and C146 partners in the disulfide bond reveals that C57 is embedded in the 
polar-rich sequence of Loop IV that is responsible for binding the Zn+2 ion. In the 
absence of a Zn+2 ion, Loop IV adopts a disordered conformation205, which may serve as 
a source of friction as others have observed195,197. However, a more plausible source of 
friction could be the nonpolar sequence of β8 adjacent to C146. Perhaps this sequence, 
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when not constrained by the disulfide bond, forms fleeting interactions with one or more 
of the 7 remaining β-strands, giving rise to chain friction.  
A recent peptide dissection analysis of SOD1 from our lab provides a surprising 
alternative206. The 35 residue C-terminal peptide, containing the polar sequence of Loop 
VII and the nonpolar sequence of β8, folds on itself to bring the polar and charged N-
terminus and the nonpolar C-terminus into a nonnative juxtaposition. Deletion of the N-
terminal 5 amino acids or the replacement of isoleucine 149 with threonine disrupts the 
interaction, and the peptide expands. The conjecture that β8 is primarily responsible for 
chain friction is consistent with the observation that both folding and unfolded reactions 
of 2SH-mSOD1 are slowed by friction. Previous work from the Oliveberg laboratory 
mapped the structure of the TSE onto β2, β3, β4, and β7, the internal strands on both 
faces of the β-sandwich (Fig. 3.1)207. Thus, Loop VII and β8 would be released prior to 
the TSE in unfolding and not engage after the formation of the TSE in folding, enabling 
the C-terminus of SOD1 to collapse on itself and introduce chain friction for both 
reactions.  
 
The link between internal friction, aggregation and ALS in SOD1 
Intramolecular interactions that give rise to friction have the potential to become 
intermolecular interactions that could drive aggregation under appropriate conditions. 
There are two lines of evidence supporting a primary role for the C-terminus of SOD1 in 
aggregation and toxicity in ALS. Work by Ivanova et al. showed that only a hexapeptide 
containing residues 147-153 from β8 accelerated fibril formation of both wild-type metal-
free SOD1 and ALS-linked mutants of SOD1138. The relevance of a unique role for β8 in 
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the aggregation of SOD1 is also evident in the observations of Furukawa et al.139, who 
found that the segment containing β8 and portions of the preceding Loop VII was the 
only region resistant to proteolysis in aggregates of ALS variants of SOD1 isolated from 
mouse motor neurons. 
It should be noted that other segments of SOD1, e.g., β1-β3 and β5-β6, are also 
protected against proteolysis when the aggregates are artificially created in vitro139. These 
regions are also the only regions protected in the I149T variant and in mutants that 
truncate the C-terminus, such as L126Z. The observation that both of these variants cause 
ALS suggests that, in the absence of Loop VII-β8, other β-strands may serve as 
secondary sites for nucleating aggregation.  
 
SOD1 and ALS 
The nascent SOD1 chain prior to disulfide bond formation, dimerization, and full 
metalation has several properties that distinguish it from many proteins and would 
increase its propensity to aggregate. First, the reduced wild-type monomer is only 
marginally stable, resulting in ~1% of the population occupying the unfolded state at 
equilibrium91. ALS mutations dramatically destabilize the native state, resulting in a 
preponderance of the unfolded state at neutral pH and physiological temperatures88. The 
dramatic shift to the unfolded state of SOD1 is compounded by its exceedingly slow 
folding reaction, τ > 10 s in the absence of denaturant93. The long lifetime and 
preponderance of the unfolded nascent chain in SOD1 ALS-variants would enhance the 
probability for the same sequences that give rise to intramolecular friction to form 
intermolecular interactions and nucleate aggregation138,139. The nascent chain, with its 
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nonnative collapsed structure at the C-terminus, would be a nearly universal target for 
therapeutics designed to ameliorate the deterioration of motor neurons in ALS caused by 
mutant forms of SOD1.   
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Chapter IV –Disulfide bonds protect against aggregation, but 
induce complex folding mechanisms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is adapted from a manuscript currently in prep: 
 
Strained disulfide bonds in VH domains create complex folding free energy surfaces 
Cohen NR, Kao YH, Matthews CR. 
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INTRODUCTION 
The broad family of antibody molecules are the crucial component of the adaptive 
immune response, and engineered variants represent a growing portion of the therapeutic 
market. Currently there are 80 FDA-approved antibody biologics for a host of human 
diseases (drugs@FDA). Of these 35 are natural murine or human antibodies, 10 are 
chimeric antibodies containing murine variable domains attached to human constant 
domains, and 35 are “humanized”, meaning they contain recognition sequences from 
murine antibodies appended to human scaffolds111. The latter group of hybrid molecules 
presents an interesting class of proteins whose sequences were not evolved through the 
natural processes of antibody maturation. Removing these variable domains from the 
optimization of adaptive immunity may result in proteins with unanticipated and possibly 
deleterious biophysical properties. Our lab recently found a complex folding free energy 
surface in a de novo designed βα protein with a natural topology, highlighting the 
challenges that can arise in protein design and engineering208. 
Human antibodies are formed through the covalent association of four 
polypeptide chains, two Heavy Chains (HC) an two Light Chains (LC). Each LC pairs 
with a HC partner, forming a disulfide-crosslinked heterodimer, that then forms disulfide 
crosslinks with another heterodimer to form the full antibody. Each chain is comprised of 
a series of tandem domains, 4-5 in the HC and 2 in the LC. The N-terminal variable 
domain, VL in the LC and VH in the HC, is responsible for antigen recognition and 
binding. Following in sequence are the constant domains, CL in the LC and CH1-3/4 in the 
HC, that are responsible for the formation of the full antibody and also stimulate the 
immune response upon antigen binding. The constant domains are highly conserved 
 107 
between different antibodies on the same class, such as the IgMs or IgGs, while the 
variable domains are unique to each antibody.  
Each of the variable and constant domains contain the canonical immunoglobulin 
fold, Ig-fold, defined by 7-9 antiparallel β-strands that form a pair of opposing β-sheets 
linked by a highly conserved intramolecular disulfide bond (Figure 1)97,98. The VH 
domains fold autonomously, while the VL constant domains often require chaperones or 
partners to fold209–213.  
A recent study of a humanized IgG1 monoclonal antibody (mAb) found a 
significant population lacked an intramolecular disulfide (SS) bond in the VH domain 
115,214. Similar behavior has been observed in another IgG1 antibody215, an anti-IgE 
molecule116 and several other antibodies216,217 suggesting this may be a common 
phenomenon in engineered antibodies. In the anti-CD20 molecule, the absence of the SS 
bond did not have an impact on binding, however, the anti-IgE molecule experienced a 
significant reduction in binding efficacy. One could imagine that the absence of the SS 
bond would also alter the stability of the VH domain and potentially lead to unfolding and 
aggregation. 
To understand the heterogeneity in the SS bond content in these mAbs, we chose 
to examine the isolated VH domains of the two antibodies that do not completely form the 
SS bond as well as one that does. Approximately 30% of the VH domains from the IgG1 
mAb A115 (VHA) and 50% of the VH domains from the anti-IgE mAb B (VHB)116 do not 
form intramolecular SS bonds while the VH domains of mAb C (VHC) contain a fully 
formed SS bond116. The synthesis of a VH domain prior to the remaining HC sequence 
and its autonomous folding reaction rationalized this strategy. We propose that the failure  
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Figure 4.1: Structure of a VH domain 
A ribbon diagram of a VH domain, adapted from PDB 1N8Z99, is shown. The 
complementarity determining regions 1-3 are shown in red, blue, and purple. The disulfide 
bond is shown in yellow.  
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to completely form the SS bond in the VHA and VHB domains is best understood as a 
consequence of the unanticipated strain required to form the SS bond. The introduction of 
the SS bond in these domains also results in a complex folding reaction involving 
residual structure in the unfolded state, a folding intermediate and parallel folding 
channels.  
 
RESULTS 
The failure to completely form the intramolecular disulfide in the two VH domains 
could reflect the thermodynamic and/or kinetic properties of the disulfide reduced (2SH-) 
or disulfide oxidized (SS-) forms of these domains. To gain a comprehensive 
understanding of the interplay between folding and SS bond formation we performed 
classical kinetic and thermodynamic analyses of both the 2SH- and SS-forms of these VH 
domains.  
 
Analysis of the folding and stability of the 2SH-VH domains 
To determine if the biophysical properties of the 2SH-VH domains explain the 
heterogeneity of the SS bond formation observed in mAb A and mAb B, we examined 
the thermodynamic and kinetic folding properties of VHA and VHB and those of VHC that 
completely forms the SS bond. The 2SH forms of the 3 domains were prone to 
aggregation at the micromolar concentrations required for circular dichroism (CD) 
analysis, requiring fluorescence spectroscopy (FL) to monitor the folding reactions. 
Although the reduced proteins were amenable to kinetic refolding studies at nanomolar 
concentrations, prolonged exposure to refolding conditions for equilibrium studies also 
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led to aggregation. Thus, we were only able to obtain a partial chevron plot, i.e. log 
relaxation time vs. final denaturant concentration, by refolding from highly denaturing 
urea solutions and monitoring the reaction before the onset of aggregation. The chevron 
plots for 2SH-VHA, 2SH-VHB and 2SH-VHC are shown in Figure 4.2A-C. 
 The refolding reactions of 2SH-VHA, 2SH-VHB and 2SH-VHC were well described 
by single exponential responses and the denaturant dependences yielded simple chevrons 
consistent with a two-state mechanism, N↔U. Fits of these chevrons to a two-state 
model provided the refolding and unfolding relaxation times in the absence of denaturant 
as well as the denaturant dependence of the relaxation times, the m-values (Table 4.1). 
We found 2SH-VHA and 2SH-VHB fold within 100’s of milliseconds, while 2SH-VHC 
folds far slower, on the order of 10’s of seconds. The maxima in chevron plots 
corresponds closely with the midpoint of the equilibrium unfolding reactions, Cm, an 
indicator of the stability of the protein to chemical denaturation. Comparison of the 
maxima of the partial chevrons shows the rank order of stability to be 2SH-VHA > 2SH-
VHB > 2SH-VHC.  
 
Analysis of the folding and stability of the SS-VH domains 
Thermodynamic Analysis 
To gain a comprehensive understanding of the differential behavior of these 
engineered proteins, we also examined the thermodynamic and kinetic properties of the 
three SS-VH domains. We collected equilibrium denaturation curves for SS-VHA, SS-VHB, 
and SS-VHC using FL lifetime detection (Fig. 4.3A-C). The equilibrium curves of both 
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Figure 4.2: Chevron plots of the 2SH-VH domains 
Chevron plots of 2SH-VHA (A, red) and 2SH-VHB (B, purple), obtained with stopped-flow 
FL, are shown with two-state fit to the data (solid line). Preliminary chevron of 2SH-VHC 
(C, brown), obtained with manual-mixing FL, is shown with an approximate fit to the data 
(dashed line).
A
B
C
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The parameters obtained from fitting the chevron plots of 2SH-VH domains are shown. The extrapolated refolding, τf, and 
unfolding, τu, relaxation times and the errors of the fit to the chevron plots (Fig. 4.2) are shown in seconds. The fits and errors 
for the refolding, mf‡, and unfolding, mu‡, portions of the chevron plots are shown in kcal mol-1 [D]-1. The free energies of folding, 
ΔG‡eq, were calculated from the kinetic data and are shown in kcal mol-1. The denaturant dependence of the free energy of 
folding, meq‡, calculated as, meq‡= mf‡- mu‡ is also shown in kcal mol-1 [D]-1. The midpoint, Cm, of each titration is shown in 
[Urea] (M).  
1The VHC parameters are from an approximate fit to preliminary data 
 
Table 4.1: Kinetic Parameters for the folding reaction of the 2SH-VH domains
τf mf‡ τu mu‡ ΔGeq‡ meq‡ Cm
VHA 0.082 ± 0.024 0.84 ± 0.10 530 ± 1000 -0.73 ± 0.40 5.11 ± 1.49 1.57 ± 0.41 3.3 ± 1.3 
VHB 0.079 ± 0.019 0.50 ± 0.14 60 ± 170 -0.92 ± 0.81 3.85 ± 2.40 1.42 ± 0.82 2.7 ± 2.3 
VHC1 17.8 ± 2.4 1.87 ± 0.36 250 ± 110 -0.71 ± 0.22 1.55 ± 0.28 2.58 ± 0.43 0.6 ± 0.2 
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Figure 4.3: Equilibrium titrations of SS-VH domains by FL Lifetime 
The equilibrium titration of SS-VHA (black, A), SS-VHB (blue, B) and SS-VHC (green, C) 
monitored by tryptophan lifetime detection are shown with fits to the data (solid lines). The 
parameters of the fits are shown in Table 4.2. 
  
A
B
C
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SS-VHA and SS-VHB show two transitions; one occurring at < 1 M urea and the other with 
a midpoint of ~6-7 M urea. These curves were fit to a 3-state model, N↔I↔U ,and the 
extracted thermodynamic parameters are reported in Table 4.2. Similar results were 
observed using CD spectroscopy ~235 nm but the midpoint of the early transition was 
different, indicating that this step does not reflect a global folding event (Fig. 4.4A-B, 
Table 4.2). By contrast, SS-VHC FL (Fig. 4.3C) and CD (Fig. 4.4C) equilibrium 
denaturation curves show only a single transition with a midpoint of ~5 M urea. These 
curves were fit to a two-state model, N↔U, and the thermodynamic parameters are 
reported in Table 4.2.  
The pair of transitions in the equilibrium denaturation of SS-VHA and SS-VHB 
demonstrates that the SS bond introduces a partially-folded state not observed for SS-VHC 
or any of the 2SH-forms (Fig. 4.2). The lack of a fully folded baseline for the N↔I 
transition precluded a fully quantitative fit the of the data to a 3-state model. However the 
data above 2M urea could be fit to a 2-state model describing I↔U. The excellent 
agreement between the thermodynamic parameters for  the FL and CD curves (Table 4.2) 
is consistent with a global folding reaction. Further support for this conclusion was 
provided by analyzing the CD data at 220 nm (Fig. 4.5), where the secondary structure is 
the principle contributor to the ellipticity. The ellipticity at 230 nm is thought to reflect 
aromatic packing218 suggesting a more subtle rearrangement of secondary or tertiary 
structure. Conversely, the thermodynamic parameters determined from the CD and FL 
denaturation curves for SS-VHC are in good agreement (Table 4.2), confirming the N↔U 
mechanism. 
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The thermodynamic parameters obtained from fitting the urea titrations of the three SS-VH 
domains are shown. The apparent equilibrium denaturant dependence of the N⟷I 
transition, mNI-app, is shown in kcal mol-1 [D]-1 where [D] is the molar concentration of 
denaturant. The units of the apparent folding free energy of the N⟷I transition, ΔG°NI-app, 
are in kcal mol-1. These are apparent values as the lack of a well-defined native baseline 
precluded their full quantification. The equilibrium denaturant dependence and folding free 
energy of the I⟷U transition, mIU and ΔG°IU, are shown in the same units. The midpoint, 
Cm, of each transition is shown as the [Urea] (M) 
  
Table 4.2: Equilibrium Parameters for 
the folding reactions of the SS-VH domains
ΔG°NI-app mNi-app CmNI-app ΔG°IU mIU CmIU
Tryptophan Lifetime
VHA 0.08 ± 0.53 1.92 ± 0.51 0.04 ± 0.28 7.44 ± 0.22 1.12 ± 0.04 6.65 ± 0.31
VHB -0.95 ± 2.33 1.24 ± 0.41 -0.80 ± -1.9 8.36 ± 1.23 1.29 ± 0.20 6.48 ± 1.40
VHC N/A N/A N/A 6.30 ± 0.12 1.26 ± 0.03 5.00 ± 0.15
Circular Dichroism
VHA 0.84 ± 0.09 0.39 ± 0.02 2.15 ± 0.26 7.16 ± 0.21 1.06 ± 0.03 6.75 ± 0.27
VHB -0.09 ± 0.17 0.42 ± 0.03 -0.21 ± 0.41 8.46 ± 0.09 1.24 ± 0.01 6.82 ± 0.09
VHC N/A N/A N/A 6.31 ± 0.30 1.28 ± 0.061 4.92 ± 0.34
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Figure 4.4: Equilibrium titrations of SS-VH domains by CD 
The equilibrium titration of SS-VHA (black, A), SS-VHB (blue, B) monitored by CD at 235 
nm are shown and SS-VHC (green, C) monitored CD are shown with fits to the data (solid 
lines). SS-VHA and SS-VHB were monitored at 235 nm and SS-VHC was monitored at 236 
nm to monitor the ~235 nm peak characteristic of antibody domains219,220. The parameters 
of the fits are shown in Table 4.2. 
A
B
C
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Figure 4.5: Equilibrium titrations of SS-VHA and SS-VHB by CD at 220mn 
The equilibrium titration of SS-VHA (black, A), SS-VHB (blue, B) monitored by CD at 220 
nm are shown. The disruption of the β-sheets is only evident at higher concentrations of 
urea.  
  
[Urea] (M)
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Kinetic Analysis 
Further insights into the folding free energy surfaces were obtained from a kinetic 
analysis of the folding reactions of the 3 SS-domains using FL intensity and fitting the 
traces to one or more exponentials. The resulting chevron plots are shown in Figure 4.6A-
C and the parameters from the fits of these chevron plots are shown in Table 4.3. Unlike 
their 2SH-forms, SS-VHA and SS-VHB have complex chevron plots with multiple phases 
in both unfolding and refolding while SS-VHC shows simple two-state behavior.  
3 phases were observed when jumping SS-VHA from native to denaturing 
conditions; a sub-second phase with a small denaturant dependence, and two slower 
phases that display typical chevron behavior. For refolding jumps between ~2-7 M urea, 
only two phases were observed and they correspond to the refolding legs of the 2 slower 
unfolding phases. Under strongly folding conditions,  < 2 M urea, the faster refolding 
chevron rolls-over to be similar to the relaxation time for the denaturant independent 
faster phase in unfolding. The “nested” chevrons apparent between 5-9 M urea are 
evidence of parallel folding pathways221.  
We confirmed the parallel pathways by performing unfolding jumps to the 
midpoint of the nested chevrons, ~7 M urea, from different initial concentrations of 
denaturant(Fig 4.7, circles). The amplitude of the fast, urea-independent unfolding phase 
decreases progressively while the amplitudes of the faster unfolding chevron phase 
increases proportionally up to 5 M urea. Regardless of initial conditions, the faster and 
slower chevron phases maintain a constant ratio of ~80:20. This behavior is consistent 
with a pair of parallel folding reactions, an apparent 3-state reaction and a 2-state 
reaction: 
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Figure 4.6: Chevron plots of the SS-VH domains 
Chevron plots of SS-VHA (A, black) and SS-VHB (B, blue), obtained with stopped-flow FL, 
are shown with fits to the data (solid lines). For SS-VHA, the N⟷I transition is shown in 
black circles, the faster I⟷U transition is shown in grey circles and the slower I⟷U 
transition is shown in white circles. For SS-VHB, the N⟷I transition is shown in dark blue 
circle and the I⟷U transition is shown in light blue circles. The chevron plot of SS-VHC 
(C, green), obtained with manual-mixing FL and CD, is shown with a 2-state fit to the data 
(solid line). 
A
B
C
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The parameters obtained from fitting the chevron plots of SS-VH domains are shown. The extrapolated refolding, τf, and 
unfolding, τu, relaxation times and the errors of the fit to the chevron plots (Fig. 4.6) are shown in seconds. The fits and errors 
for the refolding, mf‡, and unfolding, mu‡, portions of the chevron plots are shown in kcal mol-1 [D]-1. The free energies of folding, 
ΔG‡eq, were calculated from the kinetic data and are shown in kcal mol-1. The denaturant dependence of the free energy of 
folding, meq‡, calculated as, meq‡= mf‡- mu‡ is also shown in kcal mol-1 [D]-1. The midpoint, Cm, of each titration is shown in 
[Urea] (M). *The N⟷I transitions show little to no denaturant dependence so the parameters are from an estimated fit to data.  
 
Table 4.3: Kinetic Parameters for the folding reactions of the SS-VH domains
τf mf‡ τu mu‡ ΔGeq‡ meq‡ Cm
VHA N⟷I* ~0.53 ~0.06 N/A N/A N/A N/A N/A
VHA I⟷U fast 0.09 ± 0.01 0.36 ± 0.02 1.8x104 ± 1.9x104 -0.55 ± 0.07 7.10 ± 0.62 0.91 ± 0.07 7.8 ± 0.9 
VHA I⟷U slow 0.01 ± 0.001 0.73 ± 0.02 1.9x105 ± 2.1x105 -0.64 ± 0.07 9.66 ± 0.62 1.37 ± 0.08 7.1 ± 0.6 
VHB N⟷I* ~0.123 ~0.01 N/A N/A N/A N/A N/A
VHB I⟷U 7.7x10-3 ± 1.5x10-3 0.54 ± 0.02 2.5x104 ± 2.5x104 -0.73 ± 0.07 8.72 ± 0.59 1.27 ± 0.07 6.9 ± 0.6 
VHC 0.49 ± 0.06 0.71 ± 0.03 8.9x103 ± 3.8x103 -0.54 ± 0.04 5.71 ± 0.26 1.25 ± 0.05 4.6 ± 0.3
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Figure 4.7: Fractional amplitudes of the three phases in SS-VHA unfolding and refolding 
The fractional amplitude of each phase of SS-VHA unfolding (circles) and refolding 
(squares) is shown as a function of initial denaturant concentration. The colors correspond 
to those in Fig. 4.6A. 
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The discrepancy between the midpoint of the early transition by FL lifetime (Fig. 4.3), 
CD (Figs. 4.4 and 4.5) and the relative amplitude data (Fig. 4.6 and 4.7) highlights the 
heterogeneity of this reaction and suggests that this early step reflects an ensemble of 
states within the native basin, [N1⇌N*]. The independence of the relative amplitude of 
the slower chevron phase on the initial urea concentration (Fig 4.7) reflects the absence 
of a dynamic equilibrium between the N1 and N2 states prior to unfolding.  
Evidence for parallel folding channels in refolding is provided by the observation 
of two phases under strongly refolding conditions, <2 M urea. The relaxation time of the 
faster refolding phase decreases with decreasing urea concentration in a manner that 
directly connects to the refolding leg of the slower chevron phase (Fig 4.6A). The slower 
refolding phase links directly to the urea-independent fast unfolding phase, identifying it 
as the N*àN1 reaction, the reverse of the N1àN* unfolding reactions. The persistence of 
the faster urea-dependent refolding phase at low denaturant concentrations rules out a 
single sequential reaction where the faster phase leads directly to the slower refolding 
phase. The absence of a dynamic equilibrium between the 2 unfolded states was 
demonstrated by varying the initial concentration of urea in the >7 M range and jumping 
to the same final condition at 7 M (Fig 4.7, squares). 
The distinct kinetic m-values for the chevrons (Fig 4.6A and Table 4.3) must mean the 
SS-VHA has two distinct unfolded conformations: (1) a compact unfolded state, U1, with 
residual structure and (2) a fully expanded unfolded state, U2. This conclusion is based on 
the observation that m-values reflect the change in buried surface area between 2 states in 
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a folding reaction178. In kinetic studies, the transition state ensemble, TSE, is the target 
state for unfolding and refolding reactions from folded and unfolded thermodynamic 
states, respectively. The sum of the absolute values of the kinetic m-values, mf and mu, are 
equivalent to the equilibrium m-value. The total m-value for the 3-state channel, 
0.91±0.07 kcal mol-1 M-1, is less than the ~1.45 kcal mol-1 M-1 expected for a fully 
unfolded chain of 125 residues with a disulfide bond178. By contrast, the total m-value for 
the 2-state channel is 1.37±0.08 kcal mol-1 M-1 in excellent agreement with the predicted 
value of 1.45 kcal mol-1 M-1. 
The folding kinetics of the SS- VHB (Fig 4.6B) domain resemble, in several 
respects, those for the SS-VHA domain (Fig 4.6A). For unfolding jumps a ~100 ms phase 
with almost no denaturant dependence precedes what appears to be a single, slower phase 
with a chevron dependence on the urea concentration. Refolding jumps reveal the ~100 
ms phase seen in unfolding as well as faster phase whose relaxation time decreases at 
lower urea concentration. Although definitive evidence for parallel channels in unfolding 
via nested chevrons is lacking, the pair of phases under strongly refolding conditions 
make a compelling argument for parallel channels in refolding. It may be the case that the 
relaxation times of the putative pair of chevrons in SS-VHB are too similar to resolve with 
exponential fitting of the FL intensity data. With the unfolding data consistent with an 
apparent 3-state reaction and the refolding data with parallel channels, we tentatively 
conclude that the same 2 channel folding mechanism holds for both SS-VHA and SS-VHB. 
The kinetic folding analysis for the SS-VHC domain revealed a single chevron 
response consistent with a simple 2-state mechanism (Fig. 4.6C).  																																																																							# ⇌ (																																						SS − ;,<	mechanism	 
 124 
The stability and m-value extracted from the kinetic data were in excellent agreement 
with those from the equilibrium data (Tables 4.2 and 4.3), further confirmation the 2-state 
nature of the reaction.  
 
DISCUSSION 
We study the folding mechanisms of the 2SH- and SS-forms of three VH domains 
from mAbs with the goal of understanding why 2 of these domains can exist in both the 
2SH and SS-form in the full length mAb while the third only exists in the SS-form115,116. 
 
Do the biophysical properties of 2SH-forms of the VH domains determine the size of the 
incomplete disulfide population in the full length mAbs? 
The 2SH-forms of the domains were prone to aggregation but refolding jumps at 
nanomolar concentrations revealed that these domains fold via a simple two-state 
mechanism (Figure 4.2A-C). The extrapolated refolding rates of the three domains (Table 
4.1) indicated that the folding of 2SH-VHA and 2SH-VHB are ~100-fold faster than that of 
2SH-VHC. It is tempting to speculate that the rapid folding of 2SH-VHA and 2SH-VHB is 
able to compete with SS bond oxidation, while the much slower folding of 2SH-VHC is 
unable to do so thereby providing an explanation for the presence of disulfide-reduced 
populations in mAb A and mAb B but not in mAb C. However, previous studies have 
indicated that folding drives rather than inhibits disulfide formation in Ig-fold 
proteins222,223. A possible explanation for this difference is that the folding times of the 
Ig-fold proteins in the previous studies, β2 -microglobulin222 and titin222,223, are on the 
order of seconds, similar to 2SH-VHC, rather than the hundreds of milliseconds observed 
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for 2SH-VHA and 2SH-VHB. The large difference in folding times might allow kinetic 
competition in one system, while preventing it in another. Another potential explanation 
is that antibody molecules are produced through overexpression in CHO cells224. This 
overexpression combined with the rapid folding of VHA/HB may overwhelm the natural 
disulfide isomerases leading to the formation of the disulfide-reduced population in the 
full length mAbs. However, the complexity observed in folding reactions of the SS-VHA 
and SS-VHB domains indicates there may be a preferable alternative explanation. 
 
Analysis of the biophysical properties of the SS-forms of the VHA and VHB domains 
revealed unexpected complexities  
Both equilibrium and kinetic analyses revealed that SS-VHA and SS-VHB domains 
contained surprising amounts of complexity in their folding mechanisms, while the 
folding of SS-VHC was more simple and similar to that of the 2SH-domains (Figs. 4.2A-C 
and 4.6A-C). Kinetic analysis of VHA and VHB revealed that both exhibit distinct parallel 
folding pathways that do not appear to interconvert (Figs. 4.6-4.7). The reactions of the 
SS-VHA pathways were separate and had distinct rates likely due to the presence of 
residual structure in the unfolded state of one pathway that was not present in the other. 
The folding reactions of the SS-VHB domain were only distinguishable under strongly 
refolding conditions, and therefore there was no indication of residual structure in the 
unfolded state. This is evidence that the residual structure in SS-VHA was not the sole 
cause of the parallel channels. In stark contrast, the kinetic analysis of VHC was in 
excellent agreement with the equilibrium data (Tables 4.2 and 4.3) confirming that it 
folds in a simple, two-state manner.  
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What gives rise to the complexities in the folding of the SS-VHA/HB domains? 
The complexities observed in the folding of the SS-, but not 2SH-, domains were 
unexpected. This suggests that the presence of the disulfide bond is driving the parallel 
folding pathways in VHA and VHB but not VHC. We aligned crystal structures of the three 
domains to determine if there was a structural basis for the complexity (Fig. 4.8). The 
RMSD of the alignment was excellent, 0.437 Å, due to the high sequence identity shared 
between the framework regions of three domains (Fig. 1.10). However, examination of 
the SS bonds revealed that the SS bonds of VHA and VHB are in a different orientation 
from that of the SS bond in VHC. The SS bond of both VHA and VHB are right-handed 
disulfides, defined by a positive χ3 angle, while the SS bond of VHC is a left-handed 
disulfide, defined by a negative χ3 angle225.  
Using an algorithm to calculate the disulfide strain energy (DSE) in these domains 
based on the χ-angles in the crystal structures226,227, we found that the right-handed SS 
bonds of VHA and VHB have strains of 3.81 kcal mol-1 and 4.22 kcal mol-1, respectively. In 
contrast, the left-handed SS bond in VHC had a strain of only 1.49 kcal mol-1 (Table 4.4). 
Notably, the DSE of the right-handed SS bonds, ~4 kcal mol-1, is nearly equivalent to the 
redox potential of Protein Disulfide Isomerase (PDI), -180 mV228. This would preclude a 
complete transfer of the disulfide from PDI to the VH domain, suggesting that the 
disulfide-free population in the full length mAb is due to unfavorable thermodynamics of 
the redox reaction, rather than kinetic competition between folding and oxidation. It is 
also noteworthy that the cysteines forming the SS bond, C22 and C96, directly precede 
CDR1 and CDR3 in sequence. It seems plausible that the conformation of the CDRs 
could alter the disulfide orientation resulting in strain. This strain would then lead to both   
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Figure 4.8: Alignment of the three VH domains 
The three VH domains were aligned in Pymol and the result is shown as ribbon diagrams. 
SS-VHA is in black, SS-VHB is in blue and SS-VHC is in green. The disulfide bonds are 
shown for SS-VHA and SS-VHB in yellow and for SS-VHC in orange. The crystal structures 
of the SS-VHA and SS-VHB domains were solved by Dr. Yiren Xu. The SS-VHC domain is 
adapted from PDB: 1N8Z99.  
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The parameters of the disulfide bonds in the crystal structures of the examined VH domains 
are shown. The dihedral angles along the cysteine residues of the disulfide bond are shown 
in degrees. The distance between the sulfur atoms is shown in Å. The disulfide strain 
energy is shown in kcal mol-1. The three VH domains examined in this study are in the top 
rows while the other ten domains are listed as PDB numbers and sorted by DSE from lowest 
to highest. The dashed line separates the low and high DSE groups.  
  
Table 4.4: Disulfide Bond Parameters in several VH domains 
 !1 !2 !3 Distance !-2 !-1 DSE 
VHA 171.98 116.31 65.75 2.04 163.08 65.44 3.81 
VHB 177.94 118.07 76.83 2.05 156.55 40.36 4.22 
VHC -177.69 166.16 -84.73 2.04 -165.16 166.99 1.49 
3B9V28 178.26 165.1 -81.95 2.06 -179.76 -177.24 0.81 
4U3X29 169.84 172.77 -76.01 2.08 179.8 -177.08 0.98 
3P9W30 176.15 166.11 -74.77 2.04 173.16 179.85 1.01 
5VH331 167.36 -172.05 -72.37 2.07 -175.47 176.77 1.33 
1MEL32 -170.46 172.9 -100.87 2.00 -172.12 -178.62 1.57 
1OHQ33 161.91 165.96 -65.56 2.04 172.25 -172.81 2.53 
5I0Z 176.09 111.07 74.66 2.04 169.24 58.81 2.75 
1OL034 178.49 123.96 62.12 2.10 167.19 60.54 3.73 
1T2J 163.22 122.23 65.11 2.06 169.85 60.69 4.11 
5FV235 168.79 125.27 54.14 2.04 167.24 72.03 5.32 
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the disulfide-free population in full length mAbs and the complex folding free energy 
surfaces described above. 
 
Are right-handed disulfide bonds common in VH domains? 
We compared VHA, VHB, and VHC to ten other VH domains from crystal structures 
available in the PDB and found that 6 had left-handed SS bonds with DSE<2.5 kcal mol-1 
and aligned well with the SS bond of VHC (Table 4.4, Fig. 4.9A). The other four had 
DSE>2.5 kcal mol-1 and aligned well with the right-handed SS bonds of VHA and VHB 
(Table 4.4, Fig. 4.9B). In this cursory analysis, there appeared to be a slight preference 
for left-handed SS bonds in VH domains, but a more thorough analysis would clarify any 
such trends.  
Close examination of other mAbs containing VH domains with right-handed SS 
bonds might reveal a direct connection between SS bond orientation and in the presence 
of the disulfide-free population. If so, then examination of the SS bonds of mAb crystal 
structures could provide a relatively rapid and accessible method to screen for the 
potential to form disulfide-free populations as well as complexities in the folding free 
energy surfaces. 
 
MATERIALS AND METHODS 
VH domain purification 
E. Coli cell pellets were provided by the Kao group at Genentech and Dr Xiren 
Yu developed the following purification method with minor adaptions by our group. Cell 
pellets were thawed at 4°C overnight. Cell pellets were then resuspended in 25 mM Tris   
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Figure 4.9: Disulfide Bond Orientation in other VH domains compared to SS-VHA/HB/HC 
Ten VH domains from the PDB (Table 4.4) were aligned with the three SS-VH domains in 
Pymol and then sorted by disulfide bond orientation into right-handed (A) and left-handed 
(B) groups. 
  
A B
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buffer pH=7.5 at a 1:10 w/v ratio. The resulting solution was passed through a 
microfluidizer twice to ensure complete lysis. The lysis solution was centrifuged at 
12,000 g for 15 minutes and the supernatant was collected and centrifuged at 12,000 g for 
another 15 min and the supernatant was collected. This lysate solution was loaded onto a 
series of HiTrap SP FF 25 mL columns (GE Healthcare) at a 10:1 ratio of lysate volume-
to-column volume using a BIO-RAD NGC system (BIO-RAD). In order to scale up the 
process multiple 25 mL columns were linked in series to allow greater load volumes. The 
proteins were eluted with a 0-25% gradient of 25 mM Tris, 2 M NaCl, pH=7.5 over ten 
column volumes and the peak fractions were collected. These fractions were combined 
and loaded onto a series pre-charged and pre-equilibrated HiTrap IMAC FF, 25 mL 
columns (GE Healthcare) using a BIO-RAD NGC system (BIO-RAD). The series of 
IMAC columns prevented overloading. The remaining impurities were washed off over 
12 column volumes with a buffer of 85% 50 mM Tris, 50 mM NaCl, 5 mM Imidazole, 
pH=7.5 and 15% 50 mM Tris, 50 mM NaCl, 1 M Imidazole, pH=7.5. The VH domains 
were then eluted with 15-40% gradient of the 50 mM Tris, 50 mM NaCl, 1 M Imidazole, 
pH=7.5 buffer over 15 column volumes. The resulting peak fractions were collected and 
dialyzed into the experimental buffer 20 mM MES, 50 mM NaCl pH=6.0. 
At each step along this process small fractions were collected and run by both 
SDS-PAGE and western blots to confirm the presence of the VH domains. Western blots 
were able to detect the domains using an antibody against the His-6-tag in the domains.  
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Disulfide Reduction  
Cysteines of the disulfide in the VH domains were inaccessible unless under 
strongly denaturing conditions115, so reduction was carried out by shifting the protein into 
9 M Urea, 20 mM MES, 50 mM NaCl, 1mM TCEP buffer pH=6.0 for an hour. For the 
reduced experiments all buffers used were the same with the addition of 1 mM TCEP to 
ensure reduction. 
 
Stopped Flow Fluorescence Data Collection and Analysis 
The folding kinetic experiments on VH domains were performed using an Applied 
Photophysics system and the data was collected with the Applied Photophysics Pro-Data 
software. A 357 nm 40 nm wide bandpass filter (Semrock, Rochester, NY) was used to 
detect the emission peak. Jumps of 1:10 protein: buffer ratio at 20°C were performed to 
various final amounts of urea and final protein concentrations of 150-500 nM. The nM 
concentrations were used to decouple the refolding and aggregation processes of the 
2SH-VH domains. The observed reaction times did not change across the range of 
concentrations examined, indicating that they are unimolecular folding reactions. Similar 
experiments were performed for the refolding and unfolding of the SS-VH domains. For 
accurate detection of the millisecond reactions the drive pressure was held constant 
throughout the experiment to prevent back mixing artifacts in the data. Each experimental 
run involved >10 jumps to each final urea concentration and each experiment was 
performed >3 times. 
The initial folding and unfolding reactions were monitored on a log scale from 
milliseconds to 100’s of seconds to ensure the entire reaction was captured. Once the 
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reaction time was assessed, smaller time windows were used to obtain denser data sets. 
The resulting traces were independently fit to the necessary exponentials until the data 
was well described using in-house software (available upon request). In many traces a 
linear term was required to account for photobleaching of the sample. The time constants 
of the from the >10 fits for each final concentration of denaturant in an was then averaged 
to obtain the relaxation time at that point. These were recorded and plotted as a function 
of final denaturant concentration to obtain the chevron plots in Figs. 4.2 and 4.5. The data 
point of the chevrons represent the average of >3 experiments to each final concentration 
of denaturant and the error bars denote the standard deviation.  
 
Chevron Plot Analysis  
The chevron plots were input and fit to the following equation using SigmaPlot 
software and the results of the fits were reported in Tables 4.1 and 4.3: 
																																								 1ABCD = FBCD 	= 	 1FGHIJKLM[N]OP Q + FSHITKLU[N]OP V	 																											WX. 4.1 
Where τobs is the observed time constant from the fit and its inverse, kobs is the observed 
rate constant, kf0 is the folding rate constant in the absence of denaturant, mf is the 
denaturant dependence of the refolding rate constant, ku0 is the unfolding rate constant in 
the absence of denaturant, mu is the denaturant dependence of the unfolding rate constant, 
[D] is concentration of urea, R is the ideal gas constant and T is temperature. 
The fits of the chevrons were recorded and used to calculate the free energy of folding of 
each domain with the following equation 
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The total denaturant dependence of the free energy of folding, meq, was calculated as mf-
mu. The midpoint of each reaction, Cm, was calculated as ∆G0/meq.  
To fit the 2SH-chevrons, a maximum value of meq was estimated using the 
methods described by Myers, Pace and Sholtz178. This was used as an upper limit to 
allow the fitting routine to function with an estimated value of mu despute being based on 
solely refolding data. 
 
Equilibrium FL Lifetime Data Collection and Analysis 
The equilibrium FL lifetime data were collected using excitation by tripled output 
from a Ti:sapphire laser at 3.8 MHz repetition rate as previously described140,147,206. The 
excitation power was kept below several hundred μWatts at 292 nm. Counting rates in the 
detector channel were kept to less than 1×105 counts per second. A 357 nm 40 nm wide 
bandpass filter (Semrock, Rochester, NY) was used to select the emission peak. 
The samples were prepared from protein stocks in buffer and in ≥9 M urea and 
mixed precisely into a 96-well microplate using a Hamilton Microlab 500 titrator and in-
house software. The plates were allowed to equilibrate for several hours. Equilibrium 
measurements were performed with a home-built autosampler running custom LabVIEW 
software (available upon request) to the lifetime instrument. The samples were brought 
into a flow cell (1mm×1mm) using a Hamilton Microlab 560 dual syringe pump and 
oscillated at a flow rate of 10 μL/s during data collection to reduce exposure of the 
sample to the beam and minimize photobleaching. The FL lifetime at each point was 
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calculated by first moment analysis of the measured decay curves using in-house 
software. The resulting plots were fit to two-state or three-state mechanisms using in-
house software to determine the ∆Geq0 and meq for each transition. The midpoints of the 
transitions were calculated as described above. 
 
Equilibrium CD Data Collection and Analysis 
The equilibrium CD data were collected on a Jasco J-810 CD spectrophotometer 
(Jasco Inc.). Samples were prepared as described above and the far-UV CD spectra was 
monitored from 215-260 nm in 0.2 cm pathlength synthetic fused silica cuvette using a 
scan rate of 20 nm min-1 and a response of 8 seconds. The refractive index of each sample 
was measured and used to determine the final denaturant concentration of urea. The CD 
signal was converted to mean residue ellipticity and observed as a function of final urea 
concentration. The CD spectra of the VH domains contained a positive peak ~235 nm 
which was used to monitor their unfolding as previously described219,220. The resulting 
plots were fit to two-state or three-state mechanisms using in-house software to determine 
the ∆Geq0 and meq for each transition. The midpoints of the transitions were calculated as 
described above. 
 
Fractional Amplitude Analysis  
Jumps were performed as described above except the final denaturant 
concentration was held constant at 7 M urea and the initial concentration varied from (1) 
0à5 M urea in unfolding and (2) 8.5à9 M urea in refolding. >10 jumps from each 
initial concentration were collected and fit as described above. The average amplitude 
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associated with each time constant was divided by the sum of all the amplitudes to obtain 
the fractional amplitude of each species. These fractional amplitudes was plotted as a 
function of initial concentration of urea. 
 
VH Domain Alignment  
The crystal structures of the VHA and VHB domains were solved by Dr. Xiren Yu 
at Genentech which she graciously provided for our use. The domains were aligned in 
Pymol and the RMSD was recorded. The other VH domains were obtained from the listed 
PDB entries and were aligned in the same way.  
 
Disulfide Strain Energy Calculation  
The disulfide strain energy of each domain was calculated using the following 
equation based on the AMBER force field229,230:  abW = 2(1 + def(3h$)) + 2(1 + def(3hK$) + (1 + def(3h8)) + (1 + def(3hK8))+ 3.5(1 + def(2hk)) + 0.6(1 + def(3hk)																																				WX	4.3 
Where DSE is the disulfide strain energy in kcal mol-1 and χ1,2,3,-2,-1 are the dihedral 
angles of the cysteine residues in the disulfide bond. The dihedral angles were determined 
from the PDBs using the “Disulfide Bond Dihedral Angle Energy Server” available at 
https://services.mbi.ucla.edu/disulfide/.  
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Chapter V – Discussion 
REVIEW 
The goal of the research presented above was to examine the folding of several 
proteins with similar topologies to gain insight into where in the folding process 
opportunities for misfolding and aggregation arise. We selected the series of proteins 
SOD1 and the VH domains of mAb A,B, and C that all adopt an Ig-fold. The Ig-fold is a 
β-rich structure found throughout nature and is used in numerous proteins with diverse 
functions. Perhaps most notably, this fold is used by that antibody molecules that form 
the backbone of adaptive immunity. Ig-fold proteins are especially attractive candidates 
for this type of research as they are linked to human diseases typically characterized by 
aggregation. Furthermore, due to their natural role in the immune response, they are often 
used in protein engineering efforts focused on the creation of novel therapeutics. Any 
insights into the interplay between productive folding and deleterious aggregation of Ig-
fold proteins could prove invaluable in disease treatment and therapeutic development.  
In Chapter II, the link between the productive folding and harmful aggregation of 
the ALS-linked protein, SOD1, was explored through the characterization of a set of 
peptides serving as a model for the behavior of the nascent polypeptide chain. End 
labeling each peptide with a FRET donor-acceptor pair and monitoring the excited-state 
lifetime decay of the donor allowed the calculation of the trFRET efficiency. 
Examination of the response of the trFRET efficiency of each SOD1 peptide to 
denaturant found that the peptide containing the Loop VII-β8 region at the C-terminus of 
SOD1 demonstrated a unique sensitivity to denaturant. Utilizing a two-dimensional form 
of maximum entropy modeling to simultaneously fit the donor-only and donor-acceptor 
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lifetime decays allowed the amplitude to be assigned to species with discrete energy 
transfer and donor decay rate constants. This analysis revealed that the Loop VII-β8 
peptide in aqueous conditions contains populations of both compact and expanded states. 
The compact state was only marginally stable and its population shifted into the 
expanded state in a two-state-like manner in response to even small amounts denaturant. 
Two variants of the Loop VII-β8 peptide, one containing the ALS-linked mutation I149T 
and another truncating the polar residues of Loop VII, were examined and the trFRET 
efficiency of both was found to be insensitive to denaturant. 2DMEM analysis further 
confirmed that neither variant formed the compact state seen in the WT peptide. 
These results indicate that the very C-terminus of SOD1 was capable of forming 
nonnative structure in the absence of the rest of the sequence. Surprisingly, alteration of 
residues in either hydrophobic stretch of β8 or the polar region Loop VII was able to 
prevent the formation of this nonnative structure. The simplest explanation for this 
observation is that the nonnative state is defined by an atypical interaction between these 
two dissimilar regions. We proposed that the intramolecular interactions that form this 
species could swap with other polypeptide chains, thereby becoming intermolecular 
interactions that may be a precursor to toxic aggregation. This model could prove useful 
in searching for new therapies.  
Chapter III discussed the work probing the behavior of the SOD1 polypeptide 
chain by monitoring the response of the SS- and 2SH-mSOD1 to denaturant in the 
presence of the kosmotropes, glycerol and glucose. The initial aim was to identify any 
other transient or marginally stable species populated during the unfolding and refolding 
of SOD1, yet no such species were observed. In all the glycerol and glucose 
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concentrations examined, the equilibrium titration and kinetic folding jumps were well-
described by a two-state reaction. Interestingly, we observed that the free energy of 
folding and the denaturant dependence of the free energy of folding were found to vary 
linearly with increasing molar amounts of viscogen. By introducing parameters to 
describe the viscogen dependence of the free energy of folding and the viscogen 
dependence of the denaturant dependence, we developed a novel method of globally 
fitting chevron data in the presence of viscogens. Using this method to globally fit the 
SS-mSOD1 and 2SH-mSOD1 data, we found that the folding and unfolding of 2SH-
mSOD1 was limited by internal chain friction but disulfide-oxidized SOD1 was not.  
This finding implicates the regions constrained by the disulfide bond, Loop IV 
and β8, as drivers of the internal friction. When considered in context with the results of 
the peptide analysis from Chapter 2 discussed above, the sequence of β8 appears to be the 
most likely driver of internal friction, which may be a consequence of this region 
adopting a nonnative structure. In the broader context of SOD1-linked ALS, these results 
suggest that the C-terminal region of SOD1 is a potential origin of early misfolding and 
aggregation. Interestingly, this conclusion is supported by the observations that (1) a 
short peptide from β8 nucleates in vitro aggregation138, (2) this region is the core region 
protected from proteolysis in in vivo aggregates139 and (3) a peptide similar to the one 
used in our trFRET studies, spanning residues 131-153, was used to develop an antibody 
that specifically recognizes misfolded variants of SOD172,152.  
Chapter IV describes the preliminary results of the examination of three VH 
domains from therapeutic antibodies, two that contain 2SH-populations in the full length 
mAb and one that does not. Classical kinetic and thermodynamic analyses of these three 
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domains revealed surprising distinctions between their folding mechanisms. In each of 
the three domains the 2SH-forms were found to fold in simple, two-state manner. 
However the SS-forms of the domains that formed the 2SH- populations had complex 
folding free energy surfaces that were tied to the presence of the disulfide bond. 
Examination of the disulfide bond in the crystal structures of these domains suggested 
that the complexities arise from the formation of strained disulfide bonds.  
Interestingly, these results indicate that the strained disulfide bond in the two VH 
domains is both protective and disruptive. The disulfide bond protects the domains from 
aggregation at the cost of disrupting their otherwise simple folding reactions. We 
speculate that examination of the orientation of disulfide bonds in mAbs may provide a 
valuable tool for determining whether their individual domains have complex folding free 
energy surfaces.  
 
IMPACT 
 The work described above could have substantial impact in the ALS and antibody 
development fields. 
 In the ALS field, the compaction of the C-terminus of SOD1 presents a new target 
for the development of therapeutics aimed at treating the source of disease. The currently 
available therapeutic options for ALS only modestly slow disease progression and their 
exact mechanism of action remains unclear. However, therapeutics specifically designed 
to disrupt the compact state might inhibit the early steps of aggregation, thereby 
significantly hindering the onset and progression of the disease. Such therapeutics might 
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even be useful as a form of early intervention in families with known ALS-linked SOD1 
genetic variants.  
 The observation of a potential link between strained disulfides in VH domains and 
free thiols in mAb populations could have a remarkable impact on the future of antibody 
development. As screening methods and technology have advanced, there have been 
more frequent observations of heterogeneity in therapeutic antibody molecules. Such 
heterogeneity can have negative impacts on therapeutic efficacy and is likely involved in 
the huge financial and time costs of successfully developing new therapeutics. The 
population of mAbs containing unformed disulfide bonds discussed in Chapter 4 being an 
example of such heterogeneity that has been observed frequently in recent 
years115,214,215,217,231,232. By suggesting a potential source of the population lacking 
disulfide bonds, this work could allow future antibody engineering and development 
research to identify methods to avoid the formation of such populations entirely.  
 Beyond this potential impact, the work discussed in Chapter 4 above is, too this 
author’s knowledge, the first noting the variability of the disulfide orientation in the 
domains of immunoglobulins and the first examining the role of strain in the disulfides. 
In current research, the concept of disulfide strain is primarily connected to redox or 
allosteric mechanisms227. Studies often classify the disulfide bonds of immunoglobulins 
as “structural disulfides” and do not examine the role of disulfide strain in this group 
further233. The above work suggests that even in disulfides viewed as “structural” high 
disulfide strain energies can have an impact with significant biological consequences. A 
more thorough examination of structural disulfides, especially those in immunoglobulin 
domains, may prove to be a novel research focus in the future.  
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FUTURE DIRECTIONS 
Moving forward with these results presents several possibilities for future 
research studies. 
One option is to explore the role of the nonnative structure at the C-terminus of 
SOD1 in driving aggregation. Mapping the point at which the intramolecular interactions 
are replaced with intermolecular interactions would provide further insights regarding 
how this region nucleates the aggregation process. Obtaining high resolution information 
about the structure of the nonnative species and early oligomers through experiment 
would likely be complicated and technically challenging. However, the short size of the 
peptides examined, ~30 residues, would be suitable for simulation based studies. 
Combinations of simulation and experimental approaches have been used to obtain 
structural details for other diseases linked peptides such as Αβ for Alzheimer’s234, α-
synuclein for Parkinsons235, and IAPP for Type II Diabetes236. The nonnative structure 
involving crosstalk between hydrophobic and polar regions could also present the 
opportunity to develop novel force fields, most of which are currently built to drive 
native folding.  
The link between this nonnative structure and friction-limited folding in SOD1 
could also be established further. Examining the folding of a variant known to disrupt the 
formation of the nonnative structure, such as I149T-mSOD1, for friction-limited folding 
could determine whether the two observations are directly linked. Furthermore, the 
internal friction and/or the formation of the nonnative state may present an opportunity 
for identification of therapeutic agents. The Loop VII-β8 peptide could be used in a 
screen of small molecule libraries to identify compounds that disrupt the nonnative 
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structure. A similar approach has been used in our lab to screen for small molecules to 
stabilize the native dimer of SOD1, and the results of such screens might provide 
precursors to new therapies.  
Advancing the research into antibody domains could be done by performing 
comparably detailed analyses of the folding free energy landscapes of VH domains from 
other therapeutic mAbs. Doing so could reveal further evidence for unexpected levels of 
complexity in these engineered proteins. Comparison of such folding data with the 
disulfide bond strains calculated for crystal structures could provide further evidence of a 
link between the observation of disulfide strain and complex folding mechanisms.  
A similar approach could also be used to examine VL domains, as it seems 
possible that they experience similar issues with disulfide oxidation and complexities 
during folding. A bioinformatics study of disulfide orientation in variable domains of 
antibody crystal structures in the PDB could allow a direct comparison of the 
distributions of disulfide orientations in engineered antibodies versus those in naturally 
evolved antibodies. Doing so might also establish the analysis of disulfide orientation as a 
novel and rapid method for the detection of antibody variable domains susceptible to loss 
of the intrachain disulfide.  
A new form of VH domains, single domain antibodies (nanonbodies, sdAbs), are a 
subject of much attention currently237,238. sdAbs are based on antibodies from camelids 
and cartilaginous fish (e.g. sharks) comprised of only heavy chains, which allows the 
variable domains to function as monomers. Utilizing sdAbs for therapeutics would 
remove many of the complicating factors of antibody production such as glycosylation 
and proper assembly. Currently, sdAbs are characterized in the same way as mAbs, i.e. 
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with thermal melts, which leaves their true biophysical properties poorly 
understood239,240. Performing analyses similar to those described in Chapter IV on sdAbs 
would not only provide more detailed information on their biophysical properties, but 
might also be used as a basis for future engineering studies.  
 
PERSPECTIVE 
The folding free energy landscape of a protein defines the stages through which a 
nascent unfolded polypeptide chain progresses towards its productive native state and this 
landscape is itself defined by the amino acid sequence of the protein. Analyzing the 
process of folding characterizes the sequence of events occurring between the unfolded 
and folded chain, thereby providing a description of the free energy landscape. This 
landscape can then provide insights into which steps might frustrate or disrupt productive 
folding, simultaneously enabling deleterious aggregation.  
The link between folding/aggregation and human disease and medicine has long 
been established. Unfortunately, the exact mechanisms by which aggregation 
overwhelms productive folding and how this drives toxicity remains elusive. As the 
productive folding landscapes of more proteins are mapped and the mechanisms through 
which these proteins begin to explore deleterious aggregation landscapes are defined, 
insights into how to drive folding and/or disrupt aggregation will become more evident. 
Using these insights in the development and/or engineering of therapeutic agents will 
allow drastic improvements in the health and wellbeing of patients. 
 145 
The work described above is an example of how a thorough biophysical analysis 
can reveal information that will guide the creation of new medicines and accelerate the 
advancement of those that currently exist.  
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